DarioHealth Overview
DarioHealth is a global digital therapeutics company aiming to revolutionize how people with chronic conditions manage their health, with offerings that include highly rated diabetes and hypertension solutions. The companys AI-powered digital therapeutic solutions are designed to do more than simply support an individuals disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, high-quality software, coaching, and intuitive, clinically proven digital tools to help individuals improve their health and sustain meaningful outcomes. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets using a performance-based approach to improve its users health.
Cumulative Funding Raised Over Time ($)
$21.3MDec 2019
$43.7MFeb 2024
$48.8MJan 2017
$118.8MJan 2021
$144.4MJan 2025
$173.0MJul 2020
$223.0MJun 2022
$233.0MMay 2013
$247.3MMay 2023
$249.6MNov 2015
$250.4MOct 2011
$251.6MOct 2012
$255.8MSep 2014
$266.1MSep 2018
$283.6MSep 2025
Latest News
growth-positive
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
Merit Medical Systems has announced the acquisition of the C2 CryoBalloon technology from Pentax of America for $22 million. This acquisition is aimed at enhancing Merit Medicals endoscopy portfolio, particularly in the high-growth gastroenterology market. The C2 CryoBalloon is an innovative cryoablation device used for treating Barrett’s esophagus and other gastrointestinal disorders. While the acquisition is expected to cause short-term earnings dilution due to integration costs, it is seen as a strategic move with long-term growth potential. The acquisition aligns with healthcare trends towards minimally invasive treatments and positions Merit Medical favorably in the GI market.
Acquisition
growth-positive
Wall Street Analysts Predict a 42.77% Upside in DarioHealth (DRIO): Here's What You Should Know
DarioHealth Corp. (DRIO) has seen a significant increase in its stock price, closing the last trading session at $14.94, which is a 124% gain over the past four weeks. Wall Street analysts have set a mean price target of $21.33, indicating a 42.8% upside potential. The price targets range from $12.00 to $27.00, with a standard deviation of $8.14, suggesting variability in estimates. Despite skepticism about the reliability of price targets, strong agreement among analysts about the companys potential to report better-than-expected earnings supports a positive outlook. Analysts price targets are often influenced by business incentives, but a low standard deviation in targets indicates a consensus on the stocks potential movement.
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the addition of six...
DarioHealth Corp., a leader in the digital health market, has expanded its client base by adding six new employer clients across various industries. This expansion highlights the growing demand for Darios multi-condition digital health platform, which integrates care for chronic conditions such as diabetes, hypertension, and behavioral health. The company has introduced a new value-based pricing model that ties payments to member engagement and clinical progress, offering significant cost savings and improved health outcomes. Darios platform, supported by AI technology, aims to provide a comprehensive, cost-effective solution for employers facing rising healthcare expenses. The addition of these new clients underscores Darios market momentum and its position as a leading provider of value-based digital health solutions.
growth-positive
Dario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care
DarioHealth Corp., a leader in the digital health market, has announced the addition of six new employer clients, highlighting the growing demand for its multi-condition digital health platform. The company has introduced a new value-based pricing model that ties payments to member engagement and clinical progress, aiming to reduce costs and improve health outcomes. The new clients span various sectors, including manufacturing, education, advertising, and professional services, covering tens of thousands of employees. Darios platform supports multiple chronic conditions and is AI-enabled, further enhancing its market penetration and value-based care strategy.
Customers
growth-positive
DarioHealth and OneStep Announce Strategic Collaboration to Integrate Smartphone-Only, Clinical-Grade Fall Risk Assessment Technology into Dario's Digital Health Multi-Condition Platform
DarioHealth Corp., a leader in the digital health market, has announced a strategic collaboration with OneStep to integrate fall risk assessment and prevention capabilities into its digital health solutions. This collaboration aims to reduce falls and improve outcomes for high-risk populations, including those with obesity and Medicare Advantage members. By leveraging OneSteps smartphone-based motion-analysis technology, DarioHealth seeks to enhance its ecosystem, providing members with insights and education on fall risk. The partnership is expected to drive healthier members, stronger plan differentiation, and member retention, ultimately delivering higher returns on investment for DarioHealths clients.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $244.61M |
| Last funding | $17.5M |
| Stage | Public |
| Rounds | 17 |
| Investors | 13 |
Team Members
9
Employees: 201-500
Web & Social Links
| Website | www.dariohealth.com |
| Careers | Careers page |
| App Store | App Store |
| Google Play | Google Play |
Locations
Ha-Tokhen Street 8, Caesarea, Israel
London, UK
142 West 57th Street, New York, NY, USA
Photos & Videos
1 item(s)
DarioHealth Business
Business models
B2B2C, B2C, B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesDigital HealthcarePatient EngagementDigital TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Platforms & InterfacesMobileData StorageCloudArtificial IntelligenceMachine LearningTags (25)
diabetespersonalizationchronic-diseaseremote-monitoringiotmobile-applicationsdigital-healthcaremhealthpatient-engagementmhealthreal-timedata-analyticsmonitoringactionable-insightsbig-dataartificial-intelligencemachine-learningchronic-patientsmobile-platformhealthcare-providerstype-2-diabetesseniorsmental-healthdigital-therapeuticscloud-basedGeographic Markets
United KingdomNetherlandsNew ZealandAustraliaCanadaItalyUnited StatesGermanyDarioHealth Financials
$244.61M
Total funding
Undisclosed
Capital raised
$17.5M
Last funding
Public
Funding stage
17
Total rounds
13
Investors
Cumulative Funding Raised Over Time ($)
$21.3MDec 2019
$43.7MFeb 2024
$48.8MJan 2017
$118.8MJan 2021
$144.4MJan 2025
$173.0MJul 2020
$223.0MJun 2022
$233.0MMay 2013
$247.3MMay 2023
$249.6MNov 2015
$250.4MOct 2011
$251.6MOct 2012
$255.8MSep 2014
$266.1MSep 2018
$283.6MSep 2025
Private Equity Funding
PIPE
Sep 2025
$17.5M
PIPE
Jan 2025
$25.6M
PIPE
Feb 2024
$22.4M
PIPE
May 2023
$14.3M
Debt Financing
Jun 2022
$50M
OrbiMed
PIPE
Jan 2021
$70M
Nantahala Capital Management, Perceptive Advisors, Driehaus Capital Management, Pura Vida Investments, Phoenix Insurance, Farallon Capital Management, More Investment House
PIPE
Jul 2020
$28.6M
PIPE
Dec 2019
$21.3M
SternAegis Ventures (Lead)
PIPE
Sep 2018
$10.3M
Alliance Global Partners (Lead)
PIPE
Jan 2017
$5.1M
OurCrowd, Qure Ventures
PIPE
Nov 2015
$2.3M
Undisclosed Investor(s)
PIPE
Sep 2014
$4.2M
Undisclosed Investor(s)
PIPE
May 2013
$10M
Undisclosed Investor(s)
Undisclosed Round
Oct 2012
$1.2M
Undisclosed Investor(s)
Undisclosed Round
Oct 2011
$805K
Undisclosed Investor(s)
Public Offering / Exit
POEvent
Aug 2015
Undisclosed
POEvent
Feb 2013
Undisclosed
Mergers & Acquisitions
MNAEvent
Feb 2024
$30M
MNAEvent
Jan 2022
$6M
MNAEvent
May 2021
$30M
MNAEvent
Jan 2021
$31M
DarioHealth Lifecycle
Cumulative Funding Raised Over Time
$21.3MDec 2019
$43.7MFeb 2024
$48.8MJan 2017
$118.8MJan 2021
$144.4MJan 2025
$173.0MJul 2020
$223.0MJun 2022
$233.0MMay 2013
$247.3MMay 2023
$249.6MNov 2015
$250.4MOct 2011
$251.6MOct 2012
$255.8MSep 2014
$266.1MSep 2018
$283.6MSep 2025
All Events
PIPE
Sep 2025
$17.5M
PIPE
Jan 2025
$25.6M
PIPE
Feb 2024
$22.4M
PIPE
May 2023
$14.3M
Debt Financing
Jun 2022
$50M
OrbiMed
PIPE
Jan 2021
$70M
Nantahala Capital Management, Perceptive Advisors, Driehaus Capital Management, Pura Vida Investments, Phoenix Insurance, Farallon Capital Management, More Investment House
PIPE
Jul 2020
$28.6M
PIPE
Dec 2019
$21.3M
SternAegis Ventures (Lead)
PIPE
Sep 2018
$10.3M
Alliance Global Partners (Lead)
PIPE
Jan 2017
$5.1M
OurCrowd, Qure Ventures
PIPE
Nov 2015
$2.3M
Undisclosed Investor(s)
PIPE
Sep 2014
$4.2M
Undisclosed Investor(s)
PIPE
May 2013
$10M
Undisclosed Investor(s)
Undisclosed Round
Oct 2012
$1.2M
Undisclosed Investor(s)
Undisclosed Round
Oct 2011
$805K
Undisclosed Investor(s)
POEvent
Aug 2015
Undisclosed
POEvent
Feb 2013
Undisclosed
MNAEvent
Feb 2024
$30M
MNAEvent
Jan 2022
$6M
MNAEvent
May 2021
$30M
MNAEvent
Jan 2021
$31M
DarioHealth News
221 articles
growth-positive
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
Merit Medical Systems has announced the acquisition of the C2 CryoBalloon technology from Pentax of America for $22 million. This acquisition is aimed at enhancing Merit Medicals endoscopy portfolio, particularly in the high-growth gastroenterology market. The C2 CryoBalloon is an innovative cryoablation device used for treating Barrett’s esophagus and other gastrointestinal disorders. While the acquisition is expected to cause short-term earnings dilution due to integration costs, it is seen as a strategic move with long-term growth potential. The acquisition aligns with healthcare trends towards minimally invasive treatments and positions Merit Medical favorably in the GI market.
Acquisition
growth-positive
Wall Street Analysts Predict a 42.77% Upside in DarioHealth (DRIO): Here's What You Should Know
DarioHealth Corp. (DRIO) has seen a significant increase in its stock price, closing the last trading session at $14.94, which is a 124% gain over the past four weeks. Wall Street analysts have set a mean price target of $21.33, indicating a 42.8% upside potential. The price targets range from $12.00 to $27.00, with a standard deviation of $8.14, suggesting variability in estimates. Despite skepticism about the reliability of price targets, strong agreement among analysts about the companys potential to report better-than-expected earnings supports a positive outlook. Analysts price targets are often influenced by business incentives, but a low standard deviation in targets indicates a consensus on the stocks potential movement.
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the addition of six...
DarioHealth Corp., a leader in the digital health market, has expanded its client base by adding six new employer clients across various industries. This expansion highlights the growing demand for Darios multi-condition digital health platform, which integrates care for chronic conditions such as diabetes, hypertension, and behavioral health. The company has introduced a new value-based pricing model that ties payments to member engagement and clinical progress, offering significant cost savings and improved health outcomes. Darios platform, supported by AI technology, aims to provide a comprehensive, cost-effective solution for employers facing rising healthcare expenses. The addition of these new clients underscores Darios market momentum and its position as a leading provider of value-based digital health solutions.
growth-positive
Dario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care
DarioHealth Corp., a leader in the digital health market, has announced the addition of six new employer clients, highlighting the growing demand for its multi-condition digital health platform. The company has introduced a new value-based pricing model that ties payments to member engagement and clinical progress, aiming to reduce costs and improve health outcomes. The new clients span various sectors, including manufacturing, education, advertising, and professional services, covering tens of thousands of employees. Darios platform supports multiple chronic conditions and is AI-enabled, further enhancing its market penetration and value-based care strategy.
Customers
growth-positive
DarioHealth and OneStep Announce Strategic Collaboration to Integrate Smartphone-Only, Clinical-Grade Fall Risk Assessment Technology into Dario's Digital Health Multi-Condition Platform
DarioHealth Corp., a leader in the digital health market, has announced a strategic collaboration with OneStep to integrate fall risk assessment and prevention capabilities into its digital health solutions. This collaboration aims to reduce falls and improve outcomes for high-risk populations, including those with obesity and Medicare Advantage members. By leveraging OneSteps smartphone-based motion-analysis technology, DarioHealth seeks to enhance its ecosystem, providing members with insights and education on fall risk. The partnership is expected to drive healthier members, stronger plan differentiation, and member retention, ultimately delivering higher returns on investment for DarioHealths clients.
Partners
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, and OneStep, the U.S. Food and Drug...
DarioHealth Corp., a leader in digital health, has announced a strategic collaboration with OneStep, an FDA-listed platform, to integrate fall risk assessment and prevention capabilities into DarioHealths digital health solutions. This collaboration aims to enhance Darios ecosystem by providing at-risk members with insights and education on fall risk, ultimately improving outcomes for high-risk populations, including those with obesity and Medicare Advantage members. The integration of OneSteps AI-powered technology is expected to drive measurable ROI for health plans by reducing falls and improving patient engagement and independence. The partnership aligns with Darios outcomes-driven care philosophy and aims to address the significant medical costs associated with falls among older adults.
Partners
growth-positive
DarioHealth Announces Strategic Review Following Multiple Unsolicited Inbound Expressions of Interest
DarioHealth Corp., a leader in digital health solutions for chronic condition management, has initiated a strategic review to maximize shareholder value following multiple unsolicited inquiries. The company has formed a Special Committee and engaged Perella Weinberg Partners as a financial advisor to explore potential opportunities, including a sale, merger, or strategic business combination. Recently, Dario completed a $17.5 million private placement, strengthening its balance sheet and optimizing its cap table by converting preferred shares into common shares. This positions the company for future growth and strategic opportunities. The board has not set a timetable for the reviews conclusion and will not comment further until necessary.
PIPEInvestment
growth-positive
DarioHealth Weighs Big Moves After Surprise Interest From Suitors
DarioHealth Corp., a digital health company, is undergoing a strategic review following unsolicited interest from potential partners. The company has formed a special committee to explore options such as a sale, merger, or continuation as a standalone entity. Perella Weinberg Partners has been hired as a financial advisor. DarioHealth recently strengthened its financial position with a $17.5 million private placement, increasing its cash reserves to $40 million. The company has also simplified its capital structure by converting preferred stock into common shares. This strategic review is part of a broader trend of consolidation in the digital health sector. Despite the ongoing review, there is no guarantee of a deal. The companys shares were trading lower by 5.11% premarket.
PartnersInvestmentPIPEManagement Changes
growth-positive
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in digital health solutions for chronic condition management, today...
DarioHealth Corp., a leader in digital health solutions for chronic condition management, has announced a strategic review to maximize shareholder value following multiple unsolicited inquiries. The company has formed a special committee and engaged Perella Weinberg Partners as a financial advisor. DarioHealth recently completed a $17.5 million private placement, strengthening its balance sheet and optimizing its equity structure by converting preferred shares into common shares. This positions the company for future opportunities and strategic growth initiatives. The strategic review will consider various options, including a sale, merger, or continued standalone strategy. DarioHealths platform offers personalized care for chronic conditions, and the company serves health plans, employers, and consumers globally.
InvestmentPIPEPartners
growth-positive
DarioHealth Announces $17.5 Million Private Placement of Common Stock Priced At-The-Market Under Nasdaq Rules
DarioHealth Corp., a leader in the digital health market, announced a private placement for the sale of 2,713,180 shares of common stock at $6.45 per share, expected to raise approximately $17.5 million. The closing is anticipated around September 23, 2025, pending customary conditions. The funds will be used for general corporate purposes. The offering is exempt from registration under the Securities Act, and DarioHealth will file a registration statement with the SEC for the resale of shares. DarioHealths platform offers personalized care for chronic conditions, enhancing user satisfaction and retention.
PIPE
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a private placement...
DarioHealth Corp., a leader in the digital health market, announced a private placement of 2,713,180 shares of common stock at $6.45 per share, aiming to raise approximately $17.5 million. The closing is expected around September 23, 2025, subject to customary conditions. The funds will be used for general corporate purposes. The offering is exempt from registration under the Securities Act and will be registered for resale with the SEC. DarioHealth provides digital therapeutics for chronic conditions, offering personalized care through data analytics and coaching. The company aims to disrupt traditional healthcare by promoting sustainable behavior change.
Investment
growth-positive
DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market
DarioHealth Corp., a leader in the digital health market, has issued a shareholder update highlighting its strategic progress and growth opportunities. The company offers a multi-condition platform addressing diabetes, hypertension, weight management, musculoskeletal, and behavioral health. Darios commercial pipeline has grown to $67 million, driven by collaborations with third-party administrators and pharmacy managers, representing 87 million member lives. The companys focus on value-based care and proven outcomes, validated by over 90 clinical studies, positions it well in the current regulatory environment. Darios approach empowers users to manage chronic conditions holistically, enhancing user satisfaction and retention.
CustomersPartners
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today issued a shareholder update...
DarioHealth Corp., a leader in digital health, issued a shareholder update highlighting strategic progress and growth opportunities. The company offers a multi-condition platform addressing diabetes, hypertension, weight management, musculoskeletal, and behavioral health. Darios commercial pipeline has increased to $67 million, driven by collaborations with third-party administrators and pharmacy managers, representing 87 million member lives. The company is well-positioned to capitalize on market demand for value-based care, with over 90 clinical studies validating its outcomes. Darios approach empowers users to adapt their lifestyles for sustainable behavior change, leading to high user satisfaction and retention.
CustomersPartners
growth-positive
Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025
DarioHealth Corp., a leader in the digital health market, has announced the launch of five new contracts with self-insured employers, covering 107,000 lives. These contracts, which went live in the second and third quarters of 2025, highlight the demand for Darios integrated, multi-condition solutions for prediabetes, diabetes, and hypertension. The company reports significant reductions in hospitalizations, healthcare utilization, and employer costs per user. With a $67 million pipeline of opportunities, DarioHealth aims to reach 40 new client signings by the end of 2025, marking a 35% increase over 2024. This growth is seen as a key driver towards profitability and demonstrates Darios momentum in providing value-driven digital health solutions.
CustomersProduct Stage
growth-negative
DarioHealth Announces 20-to-1 Reverse Stock Split
DarioHealth Corp., a leader in the digital health market, announced a reverse stock split of its common stock at a 20-for-1 ratio, effective August 28, 2025. This move will reduce the number of outstanding shares from 47,996,572 to approximately 2,399,829. The reverse split aims to consolidate shares and potentially improve stock price stability. The companys authorized shares remain unchanged at 400,000,000. The reverse split will not affect stockholders percentage ownership or voting power, except for minor adjustments due to fractional shares. DarioHealth continues to focus on its digital therapeutics platform for managing chronic conditions.
growth-negative
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock...
DarioHealth Corp., a leader in the digital health market, announced a reverse stock split of its common stock at a 20-for-1 ratio, effective August 28, 2025. This move will reduce the number of outstanding shares from approximately 47.9 million to 2.4 million, while maintaining the authorized shares at 400 million. The reverse split aims to consolidate shares without affecting shareholders percentage ownership or voting power, except for minor adjustments due to fractional shares. DarioHealth provides digital therapeutics for chronic conditions, offering personalized care through data analytics and coaching. The company emphasizes forward-looking statements and potential risks, including regulatory approvals and market acceptance.
growth-negative
Some Analysts Just Cut Their DarioHealth Corp. (NASDAQ:DRIO) Estimates
DarioHealth Corp. (NASDAQ:DRIO) faced a significant setback as analysts downgraded their revenue forecasts for the company, reflecting a more pessimistic outlook. The revised consensus predicts a revenue of $24 million in 2025, marking an 11% decline from the previous year, alongside an increase in expected losses per share to $0.98. This adjustment follows a previous forecast of $32 million in revenue and $0.83 in losses per share. The companys price target was also reduced by 17% to $1.96, indicating growing concerns about its future performance. Compared to industry peers, DarioHealths anticipated revenue growth is notably weaker, with a forecasted annual decline of 20% by 2025, contrasting with the industrys expected 10% annual growth.
growth-positive
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
The Saudi Arabia Blood Glucose Device Market is projected to grow significantly from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, driven by a rising incidence of diabetes, increased health awareness, and government initiatives. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers are enhancing patient compliance. Key players in the market include Abbott Laboratories, Medtronic, and Dexcom Inc. The market is supported by urban centers like Riyadh and Jeddah, indicating strong potential in Saudi Arabia. Lifestyle issues such as lack of physical activity and high-calorie diets contribute to the high diabetes prevalence, prompting government campaigns for early detection and self-management.
growth-positive
Global Digital Therapeutics Market Experiencing Rapid Growth at a CAGR of ~28% by 2032 Amid Rising Demand for Personalized Healthcare| DelveInsight
The digital therapeutics market is rapidly growing, driven by the increasing demand for personalized, evidence-based digital health interventions. Factors such as the prevalence of chronic conditions, mental health issues, and the global shift towards remote healthcare are fueling this growth. Regulatory support and integration with traditional healthcare systems further validate the efficacy of digital therapeutics (DTx) solutions. Companies like Limbix Health, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, and Pear Therapeutics are key players in this market. DTx offers scalable, accessible, and engaging methods of care, leveraging data analytics and machine learning to personalize treatment and provide real-time feedback. The US leads in regulatory clarity and investment activity, with the FDA approving multiple DTx solutions.
growth-negative
DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates
DarioHealth Corp. reported a quarterly loss of $0.12 per share, missing the Zacks Consensus Estimate of a $0.11 loss. This represents a -9.09% earnings surprise. The companys revenue for the quarter was $5.37 million, falling short of the consensus estimate by 22.19%. Compared to the previous year, both earnings and revenue have declined. DarioHealths stock has underperformed, losing about 36% since the start of the year, while the S&P 500 gained 8.4%. The companys future performance will depend on managements commentary and earnings outlook. Currently, the stock holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
growth-negative
DarioHealth Reports Second Quarter 2025 Financial and Operating Results
DarioHealth Corp., a leader in the global digital health market, reported a decline in revenue for the second quarter of 2025, totaling $5.4 million compared to $6.3 million in the same quarter of 2024. Despite the revenue drop, the company is optimistic about its strong client momentum and strategic wins, expecting to secure 40 new clients by the end of 2025. DarioHealth is focusing on sustainable ARR growth through new B2B2C clients, although onboarding and revenue recognition have been slower than anticipated. The company is leveraging AI-driven process optimization to improve efficiencies and has increased its gross margin to 55%. However, due to delays, the company has adjusted its cashflow breakeven estimates to late 2026 or early 2027.
CustomersAI technology developing/using
growth-negative
Second quarter 2025 revenue was $5.4 million, compared to $6.3 million in the second quarter of 2024, and $6.8 million in the first quarter of 2025 - The...
DarioHealth Corp. reported a decrease in revenue for the second quarter of 2025, with $5.4 million compared to $6.3 million in the same quarter of 2024. Despite this, the company is optimistic about future growth due to strong client momentum and strategic wins. DarioHealth has signed 21 new clients, including a top U.S. healthcare institution, and expects to secure 40 new clients by the end of 2025. The company is focusing on building annual recurring revenue (ARR) and has a $53 million pipeline of commercial opportunities. DarioHealth is leveraging AI to improve operational efficiencies and expects to reduce operating expenses by 15% over the next 12-15 months.
growth-positive
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a $0.25 loss, marking an earnings surprise of +8.00%. The company also surpassed revenue expectations, posting $19.56 million compared to the estimated $18.10 million. Despite underperforming the S&P 500 this year, the companys favorable earnings revisions have resulted in a Zacks Rank #2 (Buy), suggesting potential outperformance in the near future. The companys earnings outlook and future revisions will be crucial in determining its stock movement.
growth-positive
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release...
DarioHealth Corp., a leader in the digital health market, announced it will release its financial results for the second quarter ending June 30, 2025. The company will host a conference call and webcast on August 12, 2025, to discuss these results. DarioHealth offers a digital therapeutics platform for managing chronic conditions such as diabetes and hypertension. The platform provides personalized interventions driven by data analytics and coaching. The company emphasizes a user-centric approach to healthcare, aiming for sustainable behavior change. The announcement includes cautionary statements about forward-looking information, highlighting potential risks and uncertainties. No new partnerships, investments, or acquisitions were mentioned in the article.
growth-positive
DarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025
DarioHealth Corp., a leader in the digital health market, announced it will release its financial results for the second quarter ending June 30, 2025. The company will host a conference call and webcast on August 12, 2025, at 8:30 a.m. Eastern Time. DarioHealth offers a digital therapeutics platform for managing chronic conditions, providing personalized interventions through data analytics and coaching. The platform is designed to deliver continuous care, enhancing user satisfaction and retention. DarioHealths solutions are available globally to health plans, employers, care providers, and consumers.
growth-negative
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx reported a quarterly loss of $0.57 per share, missing the Zacks Consensus Estimate of a $0.52 loss, marking a -9.62% earnings surprise. Despite this, the company posted revenues of $13.59 million, slightly surpassing estimates. Over the past year, CVRx has consistently exceeded revenue expectations but has only surpassed EPS estimates once in the last four quarters. The stock has underperformed, losing about 40.3% since the years start, compared to the S&P 500s 6.1% gain. The companys future stock performance will depend on managements commentary and earnings outlook. Currently, CVRx holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance.
growth-positive
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
TransMedics reported quarterly earnings of $0.92 per share, significantly surpassing the Zacks Consensus Estimate of $0.48 per share, marking an earnings surprise of +91.67%. The company also reported revenues of $157.37 million, exceeding expectations by 6.79%. Over the past four quarters, TransMedics has consistently surpassed consensus EPS estimates three times. The companys stock has risen by about 68.1% since the beginning of the year, outperforming the S&P 500s gain of 8.3%. Despite the positive earnings report, the stock holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market in the near future. Investors are keenly watching how future earnings estimates will evolve.
growth-positive
Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide
DarioHealth Corp. has entered into a strategic commercial agreement with GreenKey Health to address the $150 billion sleep apnea market in the U.S., which affects over 29 million Americans. This partnership aims to integrate Darios AI-powered cardiometabolic and behavioral health solutions with GreenKeys sleep-first approach to obstructive sleep apnea management. The collaboration seeks to improve health outcomes, reduce healthcare costs, and enhance productivity by targeting large payers and building a national network of service providers. This initiative aligns with the growing trend towards value-based care, offering a comprehensive solution for chronic condition management.
Partners
growth-positive
Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
DarioHealth Corp., a leader in the digital health market, presented four new studies at the 85th Annual American Diabetes Association Scientific Sessions. The research highlights Darios platforms effectiveness in sustaining GLP-1 weight loss and AI-powered personalization, demonstrating a significant reduction in eA1c levels from 9.0% to 6.7%. The studies show that users who discontinued GLP-1 medication maintained stable outcomes for six months, addressing a common industry challenge of rebound effects. Dario is leveraging these findings in commercial discussions with payers and self-insured employers, aiming to provide integrated solutions for chronic condition management. The companys AI technology achieved an 89% accuracy in predicting future glucose levels, underscoring its value in the GLP-1 market.
Product StageCustomers
growth-positive
DarioHealth Corp (DRIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
DarioHealth Corp reported a 17% year-over-year revenue increase in Q1 2025, driven by growth in its B2B2C channels. The company signed 14 new clients, including a national health plan and 12 employer partners, increasing its client base to 97. Non-GAAP gross margins improved to 70.5%, and operating expenses declined by 35% year-over-year. Strategic partnerships with virtual providers like Rula and Mediobis are enhancing DarioHealths service delivery. Despite sequential revenue being lower due to a shift in scope with a large client and tariff-related pressures, the company is on track to achieve operational cash flow break-even by the end of 2025.
CustomersPartners
growth-positive
DarioHealth Reports First Quarter 2025 Financial and Operating Results
DarioHealth Corp. reported a 17% year-over-year increase in first-quarter revenue, reaching $6.75 million, driven by growth in employer and health plan segments. The company improved its gross margin and reduced operating expenses, aided by AI-driven process optimization. DarioHealth signed 14 new clients, including a national health plan and two pharma companies, and expanded its platform with new solutions. The company refinanced debt and raised equity, enhancing its financial flexibility. DarioHealth aims to achieve operational cash flow breakeven by the end of 2025, supported by existing account expansion and new contract wins.
CustomersPartnersInvestmentExpand
growth-positive
First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially....
DarioHealth Corp. reported a 17% year-over-year revenue increase in Q1 2025, driven by growth in employer and health plan clients. The company signed 14 new clients, including a national health plan and 12 employers, and expanded its platform through partnerships with MediOrbis and Rula. Dario is undergoing an AI-driven transformation to optimize processes and reduce costs, aiming for operational cash flow breakeven by the end of 2025. The company raised equity and refinanced debt to strengthen its balance sheet. Despite a sequential revenue decrease due to a shift in scope with a large client, Dario remains focused on strategic growth and operational efficiency.
CustomersPartnersInvestmentManagement Changes
growth-negative
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
DarioHealth Corp. reported a quarterly loss of $0.06 per share, which was better than the Zacks Consensus Estimate of a $0.07 loss. This represents an earnings surprise of 14.29%. However, the companys revenue of $6.75 million missed the consensus estimate by 10.21%. Despite surpassing EPS estimates in the last four quarters, DarioHealths stock has declined by about 8.2% since the beginning of the year, underperforming the S&P 500. The companys future performance will depend on managements commentary and earnings outlook. The current Zacks Rank for DarioHealth is #3 (Hold), indicating expected performance in line with the market.
growth-positive
Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations
DarioHealth Corp., a leader in the digital health market, has published new research in the Journal of Medical Internet Research demonstrating the effectiveness of personalized digital health interventions. The study focused on increasing flu vaccine awareness among Dario members with diabetes, a group at risk of severe flu complications. By leveraging Darios personalization capabilities, the study segmented 64,904 members into three groups, with the second group receiving more personalized and frequent messages. This group showed significantly improved awareness and vaccination rates. The research underscores the potential of personalized digital interventions to enhance member engagement and health outcomes.
growth-positive
DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025
DarioHealth Corp., a leader in the digital health market, announced it will release its financial results for the first quarter ending March 31, 2025. The company will host a conference call and webcast on May 14, 2025, to discuss these results. DarioHealth offers a digital therapeutics platform for managing chronic conditions such as diabetes and hypertension. The platform provides personalized interventions through data analytics and coaching. The company emphasizes a user-centric approach to healthcare, aiming for sustainable behavior change. The announcement includes forward-looking statements, cautioning about potential risks and uncertainties. DarioHealths solutions are available globally to health plans, employers, and consumers.
growth-positive
DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives
DarioHealth Corp., a digital health company, has secured a debt financing facility of up to $50 million from Rand Capital and Callodine Group. This financing includes an immediate $32.5 million and an additional $17.5 million contingent on revenue thresholds. The funds will refinance existing debt, provide operational flexibility, and support the companys B2B2C strategy. The agreement defers debt amortization from 2025 to 2028, allowing DarioHealth to focus on strategic growth initiatives. The company issued warrants and convertible shares as part of the deal, which is seen as a validation of its chronic care management platform.
Investment
growth-positive
DarioHealth Announces CFO Transition
DarioHealth Corp., a leading global digital health company, announced the retirement of its Chief Financial Officer, Zvi Ben-David, effective May 15, 2025. Chen Franco-Yehuda will succeed him as CFO, Treasurer, and Secretary. Franco-Yehuda brings extensive experience in corporate finance and capital markets, having previously served as CFO at Pluri Inc. Her expertise is expected to drive DarioHealths financial strategy and support its growth initiatives. The transition is seen as a positive step for the company, which has expanded its digital health platform to cover multiple conditions, including diabetes and mental health. The company is poised for continued innovation and growth under new financial leadership.
Management Changes
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief...
DarioHealth Corp., a digital health company, announced the retirement of its Chief Financial Officer, Zvi Ben-David, effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new CFO, Treasurer, and Secretary, bringing extensive experience in corporate finance and capital markets. Her previous role was at Pluri Inc., where she led financial strategy and investor relations. The transition is expected to support DarioHealths growth and expansion in digital health solutions for chronic conditions. The company provides personalized interventions for diabetes, hypertension, weight management, and more. The management change is seen as a positive step towards continued innovation and growth.
Management Changes
growth-positive
DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers
DarioHealth Corp. has announced a strategic partnership with a leading benefit administrator to deliver its cardiometabolic solution, including a GLP-1 support program and AI-driven digital health suite, to employers. This partnership, which has already started contributing to recurring revenues in Q1 2025, marks Darios first national benefit administrator partnership. It aims to address rising healthcare costs associated with metabolic conditions and expand Darios footprint in the growing GLP-1 and cardiometabolic disease markets. The collaboration is expected to unlock new distribution channels and align with payer-driven models, enhancing Darios presence in the employer market.
PartnersCustomers
growth-positive
/PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer...
DarioHealth Corp., a leader in digital health solutions, has signed a significant partnership with a major U.S. research and medical institution. This agreement, already generating revenue for 2025, marks a milestone in Darios expansion in the healthcare sector. The partnership highlights Darios leadership in AI-powered, clinically validated digital health solutions for chronic condition management. Darios platform, which includes solutions for diabetes, hypertension, and more, is recognized for its personalization and integration capabilities. This collaboration underscores the companys momentum in the employer space, with engagement rates exceeding industry averages and significant health improvements reported. The partnership is seen as a validation of Darios scalable, clinically integrated solutions, reinforcing its position as a trusted provider in the digital health market.
PartnersCustomers
growth-positive
Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion
DarioHealth Corp. has announced a significant new partnership with a major healthcare employer, marking a milestone in its expansion within the enterprise healthcare sector. The partnership involves the implementation of Darios AI-driven digital health solutions, which are designed to manage chronic conditions such as diabetes, hypertension, and musculoskeletal pain. This collaboration is expected to generate recurring revenue by 2025 and reinforces Darios position as a leader in clinically validated digital health solutions. The partnership highlights the growing demand for data-driven, personalized health platforms that deliver measurable outcomes and ROI. Darios solutions are already showing significant improvements in health metrics and engagement rates, further validating its approach in the digital health market.
PartnersCustomers
growth-positive
DarioHealth (DRIO) Upgraded to Strong Buy: Here's What You Should Know
DarioHealth Corp. (DRIO) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating a positive outlook on its earnings estimates. This upgrade reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which tracks the consensus of EPS estimates from sell-side analysts, suggests that DarioHealths earnings potential is improving. This improvement is expected to have a favorable impact on the companys stock price, driven by institutional investors who adjust their valuation models based on earnings estimates. The Zacks Rank system, known for its impressive track record, highlights the importance of tracking earnings estimate revisions for investment decisions.
growth-positive
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth
DarioHealth Corp. is highlighted as a potentially undervalued player in the digital health sector, especially as competitor Hinge Health prepares for a potential IPO with a valuation between $3-6 billion. DarioHealths AI-driven chronic care platform shows strong growth metrics, with a 32.9% revenue increase and over 80% gross margins. The companys market cap is significantly lower than what similar revenue multiples would suggest, indicating a valuation gap. Recent performance includes a 398% surge in B2B2C revenue and expanded agreements with Blue Cross Blue Shield, positioning DarioHealth for accelerated growth in 2025.
Public TradingCustomersPartners
growth-positive
/C O R R E C T I O N -- DarioHealth Corp./
DarioHealth Corp. has announced a new agreement with a large regional health plan, expanding its presence in the health plan market. This partnership, which began in January 2025, integrates Darios AI-driven digital health platform into the health plans services, focusing on cardiometabolic solutions like diabetes and hypertension management. The agreement is expected to boost Darios annual recurring revenue and further expand throughout the year. This expansion underscores the growing demand for scalable, data-driven health solutions and strengthens Darios position in the rapidly growing cardiometabolic care sector.
CustomersPartners
growth-positive
DarioHealth Corp (DRIO) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
DarioHealth Corp reported a significant revenue increase of 32.9% in 2024, reaching $27 million. The company experienced a 400% growth in B2B2C recurring revenue from employers and health plans. DarioHealth successfully integrated Twill, enhancing its digital health platform to support five chronic conditions. The company achieved a gross margin above 80% for its B2B2C business, indicating strong profitability. DarioHealth plans to reduce operating expenses by an additional 20% by Q4 2025, aiming for cash flow breakeven by the end of 2025. Despite these positive developments, the company faces risks related to its reliance on GLP-1 solutions and the need to diversify its client base.
InvestmentCustomersAcquisition
Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023. Revenue growth driven by B2B2C channel including employers and...
growth-positive
DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
DarioHealth Corp., a leader in the digital health market, reported a 32.9% increase in full-year 2024 revenue, reaching $27 million. The growth was driven by the B2B2C channel, including employers and health plans, resulting in a 300% increase in recurring revenues. The company completed a $25.6 million equity financing, boosting its cash balance to $34.5 million. DarioHealths post-merger integration and AI-powered platform advancements have strengthened its product portfolio. The company added 36 new clients, totaling 83, and forecasts a 50% net client growth in 2025. DarioHealth is implementing AI tools to reduce operating expenses by 20% by the end of 2025.
InvestmentCustomersAcquisitionPartners
growth-positive
Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Growth in B2B Recurring Revenue
DarioHealth, a digital health leader, reported a strong financial performance for the fourth quarter and full year 2024, with revenue surpassing forecasts. The company achieved a 398% year-over-year increase in B2B2C recurring revenue, driven by employer and health plan adoption of its chronic care platform. DarioHealth secured 36 new clients in 2024, achieving a client retention rate of over 90%. The company expanded its partnerships, including a significant agreement with Blue Cross Blue Shield and integration with GLP-1 weight management programs. With a cash position of $34.5 million, DarioHealth aims to reach operational cash flow breakeven by the end of 2025. The company is poised for continued growth in the digital health market, supported by strategic expansions and a focus on profitability.
CustomersPartners
growth-positive
Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula
DarioHealth Corp. has announced a strategic collaboration with Rula Health to expand access to mental health support for employers and their workforce nationwide. This partnership will allow Dario clients to access Rulas network of over 15,000 providers, covering over 120 million commercial lives through major insurance networks. The collaboration aims to accelerate the adoption of Darios behavioral health solutions in the employer channel by integrating Rulas extensive reach. This move is expected to enhance Darios B2B2C sales growth and provide a comprehensive, accessible, and effective behavioral health solution. The partnership leverages Darios AI-driven engagement and digital coaching to offer personalized, evidence-based support.
Partners
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a strategic...
growth-positive
Dario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth
DarioHealth Corp. has signed a contract with a major healthcare system to offer AI-powered chronic care management solutions to healthcare workers. This partnership is expected to contribute to Darios goal of acquiring 15 new clients by 2025. The collaboration highlights the growing acceptance of digital health solutions among healthcare professionals, who recognize the value of proactive, technology-driven care. Darios solutions aim to improve health outcomes for conditions like diabetes, hypertension, and mental health challenges. The companys AI-driven personalization and user experience are bridging the gap between traditional care models and digital interventions. This partnership marks a significant step for Dario in the digital health landscape.
CustomersPartners
growth-positive
DarioHealth to Report Fourth Quarter and Full Year 2024 Results on Monday, March 10, 2025
DarioHealth Corp., a leader in the digital health market, announced it will release its financial results for the fourth quarter ending December 31, 2024. The company will host a conference call and webcast on March 10, 2025, to discuss these results. DarioHealth offers a digital therapeutics platform for managing chronic conditions such as diabetes and hypertension. The platform provides personalized interventions through data analytics and coaching, aiming to disrupt traditional healthcare approaches. The announcement includes forward-looking statements, cautioning about potential risks and uncertainties that could affect actual results. DarioHealths solutions are available globally to health plans, employers, and consumers.
growth-positive
DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors
DarioHealth Corp., a leader in AI-driven digital health solutions, has appointed Lawrence B. Leisure to its Board of Directors. Leisure brings four decades of healthcare leadership and expertise in managed care and digital health innovation. His experience with health plans, health systems, and employer coalitions will aid Darios expansion in payer and employer markets. Leisures background includes roles at Towers Perrin, PricewaterhouseCoopers, Accenture, Kaiser Foundation Health Plan, and UnitedHealth Groups OptumInsight. He co-founded Chicago Pacific Founders, a healthcare-focused private equity firm, and the Employer Health Innovation Roundtable. His leadership aligns with Darios mission to enhance health outcomes through AI-driven care.
Management Changes
growth-positive
DarioHealth Corp. (DRIO) Expands Health Plan Reach with New Blue Cross Blue Shield Agreement
The article discusses the position of DarioHealth Corp. (NASDAQ:DRIO) among AI stocks, highlighting the transformative impact of AI on the tech sector. It emphasizes the optimism surrounding AI investments, which has maintained high stock valuations. Financial analyst Fiona Cincotta notes the divergence between software and hardware companies, with software firms benefiting from fewer restrictions. The potential reduction in regulation under the new Trump administration could further boost tech stocks. However, investors are keen on seeing returns from AI investments, with expectations for stronger revenue streams by mid-2025. The article also mentions the scrutiny of Big Tech stocks and the focus on financial returns as a measure of success.
growth-positive
Market News Alert: DarioHealth Secures Significant New Agreement, Expanding Growth in the $1.2 Trillion Dollar Cardiometabolic Market
DarioHealth has announced a significant partnership with Blue Cross Blue Shield, integrating its AI-driven digital health platform into the insurers offerings. This expansion into the $1.2 trillion cardiometabolic market is expected to boost Darios recurring revenue. The company has shown strong financial performance, with a 111% year-over-year revenue increase in Q3 2024 and a $25.6 million private placement enhancing its cash position to $40.6 million. Dario is targeting operational cash flow positivity by mid-2025 and is expanding into the $100 billion GLP-1 weight-loss market. The companys AI-powered platform is gaining traction among payers and employers, delivering measurable health outcomes.
CustomersPartnersInvestmentAcquisition
growth-positive
DarioHealth Announces New Blue Cross Blue Shield Agreement, Expanding Health Plan Client Base
DarioHealth Corp. has expanded its payer network by securing a new agreement with a Blue Cross Blue Shield health plan. This partnership enhances Darios recurring revenue growth and strengthens its position in the digital health market, particularly in cardiometabolic care. The agreement, effective from January 2025, integrates Darios AI-driven health solutions into the health plans services, contributing to the companys annual recurring revenue. With this collaboration, Dario now serves nine health plans, reinforcing its market leadership and expanding its presence in the growing cardiometabolic disease sector. The partnership underscores the demand for scalable, data-driven health solutions.
PartnersCustomers
growth-positive
PESG Report: DarioHealth Positions Itself as a Market Leader in the Multi-Billion-Dollar Digital Health Transformation
DarioHealth is making significant strides in the digital health sector with its integrated chronic care platform, which addresses multiple health conditions. The company has achieved notable financial growth, with a 111% increase in revenue year-over-year in Q3 2024 and a $25.6 million private placement. This financial boost, supported by existing shareholders and strategic biotech investors, positions DarioHealth for continued expansion and operational cash flow positivity by mid-2025. The companys data-driven approach has resulted in substantial clinical improvements and cost savings, making it a promising player in the healthcare market.
Investment
growth-positive
DarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025
DarioHealth Corp., a leader in digital health, announced the successful closing of a $25.6 million private placement of convertible preferred stock. The financing, primarily from existing shareholders and accredited healthcare investors, is expected to extend Darios cash runway and support its strategic plan to achieve operational cash flow positive by the end of 2025. The funds will bolster Darios financial position, enabling the company to focus on high-margin, scalable recurring revenues across B2B and pharma channels. The private placement closed on December 18, 2024, and January 14, 2025, resulting in a proforma cash balance of $40.6 million as of the end of Q3 2024.
Investment
growth-positive
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the...
DarioHealth Corp., a leader in digital health, announced the successful closing of a $25.6 million private placement of convertible preferred stock. The investment, primarily from existing shareholders and accredited healthcare investors, is expected to extend Darios cash runway and bolster its financial position. This funding will support the companys strategic plan to achieve an operational cash flow positive run rate by the end of 2025, focusing on high-margin, scalable recurring revenues across B2B and pharma channels. The private placement closed on December 18, 2024, and January 14, 2025, with a proforma cash balance of $40.6 million as of the end of the third quarter of 2024.
Investment
growth-negative
DarioHealth Corp (DRIO): AI Solutions for Health and Wellness
The article discusses DarioHealth Corp. (NASDAQ:DRIO) in the context of AI companies with a market cap under $2 billion. It highlights the potential and risks associated with AI, including overreliance on key players and shifts in demand towards smaller competitors. The discussion on CNBCs Fast Money raised concerns about elevated expectations for AI, particularly in the semiconductor market, with customer concentration as a significant risk. The article also touches on broader market performance, economic data, and hedge fund sentiment, emphasizing the importance of managing risks for sustainable growth. The methodology involved analyzing AI stocks under $2 billion and hedge fund interest, noting that imitating top hedge fund picks can outperform the market.
growth-positive
DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market
DarioHealth Corp. is expanding its presence in the rapidly growing weight-loss market by enhancing its GLP-1 offering with prescribing capabilities. This strategic move aims to capture a larger market share as demand for medical weight-loss solutions increases among employers and consumers. Darios shares rose by nearly 14% following the announcement, indicating strong investor confidence. The companys approach integrates behavior change programs with physician oversight, ensuring sustainable weight-loss solutions. Dario targets both employers and the direct-to-consumer market, offering a digital platform and virtual care. The company differentiates itself by focusing on behavior-first models, positioning itself as a key digital health partner for employers, consumers, and pharmaceutical companies.
Product StageCustomersPartners
growth-positive
/PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced...
DarioHealth Corp. has announced a collaboration with MediOrbis to enhance its GLP-1 behavior change solution by adding prescribing capabilities for a comprehensive medical weight loss program. This partnership aims to meet the growing demand from employers covering weight-loss medications and expand Darios market in the digital health sector. The collaboration is expected to drive recurring revenue and open new revenue streams in direct-to-consumer and pharma channels. By integrating virtual physician management, Dario aims to optimize outcomes and ROI for employers, providing a holistic and cost-effective weight management program. This strategic move positions Dario to capture more opportunities in the employer and direct-to-consumer markets.
Partners
growth-positive
DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
DarioHealth Corp. has announced a strategic collaboration with MediOrbis to enhance its GLP-1 behavior change solution by adding prescribing capabilities for a comprehensive medical weight loss program. This partnership aims to meet the growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharmaceutical channels. As more employers cover obesity medications, DarioHealths integrated solution supports direct-to-consumer offerings and expands its addressable market in the fast-growing digital health segment. The collaboration positions DarioHealth to potentially drive recurring revenue and expand its market in response to increasing employer demand for holistic, cost-effective weight management programs.
Partners
growth-positive
Dario Signs Four New Employer Contracts Across Full Product Suite
DarioHealth Corp., a leader in the digital health market, announced the signing of four new contracts with self-insured employers, set to go live in the first quarter of 2025. This move is part of Darios strategy to expand its client base by 35% in 2024, with an estimated total of 25 new client signings. The contracts cover the full suite of Darios platform, indicating the value of their multi-condition offerings. These new contracts are expected to contribute to recurring revenue and gross margin growth, enhancing Darios profitability timeline. DarioHealths platform provides personalized care for chronic conditions, aiming to disrupt traditional healthcare approaches and improve user satisfaction and retention.
Customers
growth-positive
DarioHealth Third Quarter 2024 Earnings: EPS Beats Expectations
DarioHealth reported a significant increase in revenue, reaching $7.42 million, which is up 111% from the previous quarter. The companys net loss narrowed by 13% to $12.3 million, with a loss per share improving from $0.49 to $0.30. Earnings per share surpassed analyst estimates by 8.5%. Looking forward, DarioHealths revenue is expected to grow at an average of 29% annually over the next three years, outpacing the US Healthcare Services industrys forecasted growth of 9.9%. Despite these positive financial indicators, the companys shares have decreased by 2.9% over the past week. The article also notes five warning signs for DarioHealth that should be considered.
growth-positive
DarioHealth Corp (DRIO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
DarioHealth Corp reported a significant year-over-year revenue increase of 111% in Q3 2024, reaching $7.42 million. The company achieved a gross margin of 83% in its B2B2C business and secured 10 new client contracts, with expectations to add 5 more by year-end. Despite not being cash flow positive yet, DarioHealth aims to achieve this by the end of 2025. The company is transitioning its Pharma business to a subscription-based model to enhance revenue predictability. Challenges include converting new client logos into meaningful revenues and integrating recent acquisitions. The company is undergoing organizational changes, including budget reallocations, which may impact short-term stability.
Customers
growth-positive
DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates
DarioHealth Corp. reported a quarterly loss of $0.13 per share, which was better than the Zacks Consensus Estimate of a $0.18 loss. This represents an earnings surprise of 27.78%. The company also reported revenues of $7.42 million, surpassing the consensus estimate by 1.13%. Despite these positive results, DarioHealth shares have declined by about 43.9% since the beginning of the year, underperforming the S&P 500s gain of 24.3%. The companys earnings outlook remains mixed, with a Zacks Rank of #3 (Hold), indicating that the stock is expected to perform in line with the market in the near future. The sustainability of the stocks price movement will depend on future earnings expectations and managements commentary.
growth-positive
DarioHealth Reports Third Quarter 2024 Financial and Operating Results
DarioHealth Corp. reported significant improvements in its financial performance for Q3 2024, with revenue reaching $7.42 million, marking an 18.7% increase over Q2 2024 and a 111% increase compared to Q3 2023. The growth was driven by the expansion of B2B2C revenues and successful execution of strategic initiatives. The company reduced its operating loss and achieved key client wins, including 10 B2B2C clients and two new deals in the pharma/medical device channel. The merger with Twill is expected to reduce operating expenses significantly by Q1 2025. DarioHealth is on track to achieve operational cash flow breakeven by the end of 2025. The company hosted an investor conference call to discuss these results.
CustomersAcquired-by
growth-positive
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement
DarioHealth Corp. has announced a new collaboration with a top six U.S. pharmaceutical company to utilize its Dario Connect platform. This partnership marks a shift in Darios business model from milestone-based to recurring service subscription fees. The collaboration aims to enhance patient engagement and gather insights on patient outcomes and drug effectiveness. The financial structure includes a fixed configuration fee followed by a subscription fee, allowing Dario to bring engaged patients to the pharma companys digital environment. This initiative is expected to generate recurring revenue and strengthen Darios position in the pharma channel.
CustomersPartners
growth-positive
Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population
DarioHealth Corp., a leader in the digital health market, has signed a new contract with a regional health plan in the Medicaid space. This marks Darios third Medicaid client, showcasing its ability to engage with hard-to-reach populations. The contract is expected to contribute to revenues starting in the fourth quarter of 2024. Darios platform offers personalized care for chronic conditions, which is attractive to Medicaid plans. The company plans to expand its focus on Medicaid in 2025, leveraging its success in driving user engagement and delivering value to clients.
Customers
growth-positive
DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th
DarioHealth Corp., a leader in digital health, announced it will release its financial results for the third quarter ending September 30, 2024. The company will host a conference call and webcast on November 7, 2024, at 8:30 am ET, led by CEO Erez Raphael and Chief Commercial Officer Steven Nelson. DarioHealth focuses on managing chronic conditions through its digital therapeutics platform, utilizing data analytics, AI, and personalized coaching. The announcement includes cautionary notes about forward-looking statements, emphasizing potential risks and uncertainties that could impact the companys actual results. The event is an opportunity for stakeholders to gain insights into the companys performance and strategic direction.
growth-positive
/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its...
DarioHealth Corp., a leader in digital health, announced it will release its financial results for the third quarter ending September 30, 2024. The company will host a conference call and webcast on November 7, 2024, at 8:30 am ET, led by CEO Erez Raphael and CCO Steven Nelson. DarioHealth focuses on managing chronic conditions through its digital therapeutics platform, utilizing data analytics, AI, and personalized coaching. The announcement includes a cautionary note on forward-looking statements, highlighting potential risks and factors that could affect the companys results. The event aims to provide insights into the companys performance and future plans, emphasizing its commitment to revolutionizing digital health.
growth-positive
Dario Announces Complete Integration of Twill Capabilities Across Full Multi-Condition Platform
DarioHealth Corp. has announced the full integration of Twills behavioral health and navigation capabilities into its platform, marking a significant expansion in its digital health offerings. This integration aims to provide a comprehensive solution for managing both mental and physical health conditions, enhancing personalized care and engagement. The acquisition of Twill has allowed Dario to expand its platform both vertically and horizontally, offering a holistic approach to chronic condition management. The newly integrated platform, now under the Dario brand, supports a wide range of health needs through four core offerings: Wellbeing & Navigation, Behavioral Health, Cardiometabolic Care, and Musculoskeletal Health. This development is expected to improve clinical outcomes and engagement, addressing key challenges for payers, employers, and pharma companies.
Acquisition
growth-positive
Twill by Dario to Offer a Benefit for AARP Members
DarioHealth Corp., a leader in digital health, has announced a new partnership with AARP to provide digital behavioral health solutions to AARP members. This collaboration will launch in January 2025, offering AARP members access to Darios Twill platform, which addresses mental health needs such as loneliness, stress, and anxiety. The partnership aims to meet the growing demand for mental health support among the 50-plus demographic. Darios user-centric platform is designed to simplify access to mental health care, improving engagement and health outcomes. This strategic move is expected to drive growth for DarioHealth by expanding its reach and enhancing its reputation as a provider of digital health solutions.
PartnersCustomers
growth-positive
DarioHealth Corp (DRIO) Q2 2024 Earnings Call Highlights: Strong B2B2C Growth and Strategic Shifts
DarioHealth Corp reported a 60% sequential growth in its B2B2C business from Q1 to Q2 2024, with 28% organic growth before the impact of the Twill acquisition. The company achieved 82% non-GAAP gross margins, indicating strong profitability potential. Despite a $1.1 million price concession affecting Q2 2024 revenue, DarioHealth anticipates a 70% reduction in non-GAAP operating losses by Q1 2025. The integration of Twills behavioral health expertise is enhancing DarioHealths platform, driving cross-selling success. However, the company is undergoing significant headcount reductions and cost-cutting measures. The strategic shift to a recurring revenue model is expected to stabilize future growth. The article was released on August 08, 2024.
AcquisitionCustomersLayoffs
growth-positive
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
The article discusses the investment potential of five top-ranked stocks with rising price-to-earnings (P/E) ratios, including Adverum Biotechnologies, IceCure Medical, DarioHealth, Energous, and Virgin Galactic. It highlights the strategy of investing in stocks with rising P/E ratios, suggesting that as earnings rise, so should the stock price, indicating strong growth potential. The article emphasizes that stocks with increasing P/E ratios can yield significant returns, especially when picked early in their breakout cycle. Each of the mentioned companies has shown positive earnings surprises over the past four quarters, suggesting strong performance and potential for future growth.
growth-positive
All You Need to Know About DarioHealth (DRIO) Rating Upgrade to Strong Buy
DarioHealth Corp. has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which is based on earnings estimate revisions, has a proven track record of predicting stock performance. This upgrade reflects a positive outlook on DarioHealths earnings, suggesting potential buying pressure and an increase in stock price. Analysts have been raising their estimates for the company, with a notable 20.9% increase in the Zacks Consensus Estimate over the past three months. This positions DarioHealth in the top 5% of Zacks-covered stocks, indicating its potential for market-beating returns.
growth-positive
National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors
DarioHealth Corp. has announced a significant new contract with a national Medicare Advantage health plan to launch its behavioral health solution, Twill by Dario, starting January 2025. This multi-million-dollar contract is expected to contribute significantly to Darios annual recurring revenue (ARR) growth in its B2B2C channel. The contract marks Darios first national health plan contract in the Medicare Advantage market and brings the total number of health plans Dario has contracted with to seven. The partnership aims to support healthy aging by addressing emotional health and well-being, particularly for seniors, through AI-based network navigation and digital Cognitive Behavioral Therapy (CBT) programs.
CustomersPartners
growth-positive
Zacks.com featured highlights include TAL Education, The RealReal, DarioHealth, HealthEquity and Energous
The article discusses five top-ranked stocks with rising price-to-earnings (P/E) ratios that are expected to yield stellar gains. These stocks include TAL Education Group, The RealReal, DarioHealth, HealthEquity, and Energous. The article explains that a rising P/E ratio indicates strong investor confidence in the companys future earnings potential. TAL Education Group, which provides K-12 after-school tutoring services in China, is highlighted for its strong earnings performance. The article is aimed at investors looking for stocks with strong growth potential based on their rising P/E ratios.
growth-positive
Dario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes
DarioHealth Corp. announced the integration of Twills condition-specific, expert-led peer groups into its cardiometabolic solution. This integration aims to enhance member experience and deepen engagement by providing personalized navigation capabilities. The new features allow members to join peer-to-peer condition groups, connect with healthcare experts, and access personalized educational content. This move is expected to improve outcomes-based engagement and overall health management. The integration marks a significant milestone in the Dario-Twill product offering, aiming to create a comprehensive engagement platform in the digital health market.
Partners
growth-positive
Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes
DarioHealth Corp. announced the publication of a new study in Frontiers in Endocrinology, demonstrating the effectiveness of its cardiometabolic solution for individuals with type 2 diabetes (T2D) or prediabetes and depression. The study highlights the benefits of integrating mental health support with physical health management, showing that regular walking can mitigate the negative impact of depression on blood glucose levels. The research, conducted in partnership with the University of Haifa, underscores the value of Darios data-driven approach to health management. This holistic method aims to improve clinical and financial outcomes for employers and payers.
Partners
Growth-Negative
חברת הבריאות הדיגיטלית דריו הלת' מכווצת את המרכז הישראלי ומעבירה את הפיתוח להודו
Digital health company DarioHealth is downsizing its Israeli center and moving its development to India. 15 employees involved in software development, IT, DevOps, and software testing (QA) were laid off from the Israeli center, which now employs 60 employees including data scientists and product managers, alongside management roles - human resources, finance, regulation, and marketing. Dario refused to comment on the news.
LayoffsExpand
Growth-Negative
DarioHealth Corp. (NASDAQ:DRIO) Just Reported And Analysts Have Been Lifting Their Price Targets
DarioHealth Corp. has experienced a 14% drop in stock to US$0.79 following its latest quarterly results. The companys revenues were 21% lower than analysts predicted, but losses of US$0.08 per share were 86% smaller than expected. Analysts are now predicting revenues of US$26.7m in 2024, reflecting a 39% improvement compared to the last 12 months. Losses are predicted to shrink by 22% to US$1.21. Despite the weaker revenue outlook, there was a 43% increase in the price target to US$5.50, signalling that the expected reduction in losses is a positive.
growth-positive
DarioHealth Reports Second Quarter 2024 Financial and Operating Results
DarioHealth Corp. reported its Q2 2024 financial results, showing an 8.6% increase in revenue over Q1 2024 and a 1.7% increase over Q2 2023. The companys B2B2C revenue channel saw a 315% YoY increase and a 60% sequential increase from Q1 2024. DarioHealth also made progress in collaborating with existing and potential pharma clients to transition to a more stable, recurring revenue-based business model. The company also reported strong business momentum on cross-selling of its Twill offering to Dario clients. DarioHealth expects to reduce operating expenses by approximately 40% by Q1 2025, aiding in an expected reduction in operating losses of at least 70% by Q1 2025.
CustomersPartnersAcquisitionManagement ChangesExpand
Growth-Negative
DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates
DarioHealth Corp. reported quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.29 per share. This is a significant improvement from a loss of $0.58 per share a year ago. However, the companys revenues of $6.26 million for the quarter ended June 2024 missed the Zacks Consensus Estimate by 17.37%. Despite surpassing consensus EPS estimates four times in the last four quarters, DarioHealth shares have lost about 46.1% since the beginning of the year. The future performance of the stock will depend on managements commentary on the earnings call and the companys earnings outlook.
Neutral
DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th
DarioHealth Corp., a leader in the global digital therapeutics market, announced it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. DarioHealth Corp. is a leading digital therapeutics company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform.
growth-positive
Dario Expands GLP-1 Solution Client Base with New Employer Contract
DarioHealth Corp. has announced a new contract with a national employer to provide its cardiometabolic solution to employees starting in Q3 2024. The employer, a leader in environmental services, chose Darios suite to address health conditions like diabetes, pre-diabetes, hypertension, and weight management needs. The suite also provides support for employees taking GLP-1 medication. Darios acquisition of Twill has enhanced its engagement capabilities, making it more appealing to employers, payers, and pharmaceutical companies. The company expects at least ten of its employer clients to adopt its integrated offering in the next quarter.
CustomersAcquisition
growth-positive
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
DarioHealth Corp. announced two new studies presented at the 84th Annual American Diabetes Association (ADA) Scientific Sessions. The studies showed that behavior change driven by Darios digital platform is sustainable for a 12-month period and supports clinical results for members taking a GLP-1. The data showed significant improvement in adopting healthy behaviors over a 12-month period across both groups as shown by increased tracking of healthy lifestyle behaviors. 31% of Dario members with Type 2 diabetes achieved results reflecting diabetes remission. The companys user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare.
Customers
Growth-Positive
3 Small-Cap AI Stocks to Buy Now: June 2024
The article discusses the potential of small-cap AI stocks, focusing on Aeva Technologies, Duos Technologies, and DarioHealth. Aeva Technologies, based in California, specializes in digital intelligence for automated mobility. Despite a nearly 29% slip in shares since the start of the year, analysts predict a potential doubling of sales from last years $4.31 million. Florida-based Duos Technologies, an application software company, has lost 61% of equity value over the past 52 weeks but has stabilized since the start of the year. New York-based DarioHealth, a healthcare sector company, leverages AI to address the needs of patients with chronic conditions. Despite a 28% slip in shares on a year-to-date basis, the company saw a gain of over 11% in a single session last Friday.
Investment
growth-positive
Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer
DarioHealth Corp. has announced a strategic reorganization to accelerate its commercialization efforts. The company is transitioning to a flatter organizational model, eliminating the President role and creating dedicated C-level positions for each core function. Steven Nelson has been appointed as the Chief Commercial Officer (CCO), a newly created role. Nelson will be responsible for developing and executing strategies to drive rapid commercialization. He will oversee Darios global commercial activities, including growth strategy, sales, client management, marketing, strategic partnerships, and expansion into new markets. Rick Anderson will step down as President and join the advisory board.
Management ChangesExpand
growth-positive
Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer
DarioHealth Corp. has announced a strategic reorganization to accelerate its commercialization efforts. The company is transitioning to a flatter organizational model, eliminating the President role and creating dedicated C-level positions for each core function. Steven Nelson has been appointed as the new Chief Commercial Officer, bringing over two decades of experience in scaling healthcare companies. Rick Anderson will step down as President and join the advisory board. The reorganization is aimed at bringing innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability.
Management ChangesExpand
growth-positive
DarioHealth Corp (DRIO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...
DarioHealth Corp reported a substantial growth in its core B2B2C business channel, accounting for about 71% of the companys performance revenues for the quarter. The company has successfully integrated acquisitions, leading to operational efficiencies and a faster-than-expected path to profitability. DarioHealth has secured significant contracts with major national health plans and employers, such as Cigna, Aetna, Amazon, Google, and Microsoft. Despite overall growth, the B2C business channel generated only $2 million in the quarter. There are ongoing risks and uncertainties associated with the integration of acquisitions.
CustomersPartnersAcquisition
growth-negative
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
DarioHealth Corp. reported a quarterly loss of $0.20 per share, which is an improvement from the expected loss of $0.59 per share. However, this is a decline from earnings of $0.45 per share a year ago. The companys revenues for the quarter ended March 2024 were $5.76 million, missing the Zacks Consensus Estimate by 3.23%. This is also a decrease from year-ago revenues of $7.07 million. Despite this, the companys shares have added about 0.6% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call.
Customers
growth-positive
DarioHealth Reports First Quarter 2024 Financial and Operating Results
DarioHealth Corp. reported a 59% increase in Q1 2024 revenue compared to Q4 2023, primarily due to an increase in B2B2C revenues and the addition of Twill Inc. revenues. The companys core revenue channel B2B2C saw an increase of 176% YoY and 210% sequentially from Q4 2023. The company also launched the Aetna platform, generating revenue in Q1 2024. DarioHealth Corp. expects to reduce operating expenses by 30% by Q4 2024 and anticipates reaching a breakeven run rate in the second half of 2025.
CustomersPartnersAcquisitionManagement Changes
Neutral
DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
DarioHealth Corp., a leader in the global digital therapeutics market, announced that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time. The call will be hosted by Erez Raphael, Chief Executive Officer, and Rick Anderson, President. DarioHealth Corp. is a leading digital therapeutics company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform.
growth-positive
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
DarioHealth Corp., a global digital health company, has published new research showing a significant reduction in blood glucose levels for members using its platform to manage weight alongside diabetes. The study examined data from 1,932 Dario members over a year, finding that those using a digital weight monitoring feature saw a significant reduction in blood glucose levels and BMI. The findings support the broader use of digital self-monitoring tools in diabetes management.
Customers
Growth-Positive
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
DarioHealth Corp. has announced two new contracts to provide integrated chronic condition management solutions for a national supply chain company and a regional education organization. The contracts, set to begin in the second quarter of 2024, will utilize Darios cardiometabolic suite to improve outcomes for employees with health conditions such as diabetes, pre-diabetes, hypertension, and weight management needs. The suite combines intelligent technologies with data insights to deliver personalized experiences that engage members over time for optimal results.
CustomersExpand
growth-positive
Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health
DarioHealth Corp., a leader in the global digital health market, announced the publication of two new studies in the Journal of Internet Medicine. The studies demonstrated the impact of a digital stress reduction program for teenagers. The first study showed significant improvements in perceived stress, brooding, and loneliness among teens engaged in the Digital Mental Health Intervention (DMHI). The second study found a significant reduction in stress levels among users of Darios digital behavioral health solution, particularly those who engaged in both digital CBT-based videos and breathing exercises.
Customers
growth-positive
Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health
DarioHealth Corp., a global digital health company, has announced two new contracts to provide integrated chronic condition management solutions for two national employers starting in Q2 2024. The first employer, a global private investment group, selected Darios cardiometabolic suite to improve outcomes for employees with cardiometabolic health conditions. The second employer, a national professional services company, chose Darios full suite of solutions to provide personalized support for employees with cardiometabolic health conditions and co-occurring musculoskeletal and behavioral health needs.
CustomersExpand
growth-positive
DarioHealth Corp. (NASDAQ:DRIO) Q4 2023 Earnings Call Transcript
DarioHealth Corp. reported its Q4 2023 earnings, beating expectations with a reported EPS of $-0.41 against expected $-0.54. The companys CEO, Erez Raphael, highlighted the companys multiyear strategy and the positive impact of the Twill acquisition. The acquisition is expected to accelerate DarioHealths financial profile and contribute to the growth of its B2B2C channel. The company also announced the launch of Aetna and multiple employer accounts in Q1 2024. DarioHealth ended the year with $37 million in cash and raised an additional $22.4 million alongside the Twill acquisition.
AcquisitionInvestmentManagement ChangesExpand
growth-positive
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
DarioHealth Corp. reported its financial results for Q4 2023 and the full year 2023, noting a decrease in full-year revenue from 2022 due to a managed decrease in B2C and strategic milestone revenue. However, the companys B2B2C revenue increased by 39% YoY. The company also signed multiple customers onto the Aetna platform and saw significant interest in its Dario GLP-1 Behavioral Change Program. DarioHealth also announced the acquisition of Twill, Inc. in Q1 2024, which is expected to accelerate the companys path to profitability.
InvestmentAcquisitionCustomers
growth-positive
11 Best Small Cap AI Stocks To Buy Now
The article discusses the growth potential of artificial intelligence (AI) and highlights the best small-cap AI stocks to buy now. These include NVIDIA Corporation, Alphabet Inc., Microsoft Corporation, Duos Technologies Group Inc., DarioHealth Corp., CXApp Inc., Innodata Inc., BigBear.ai Inc., and SoundHound AI Inc. The stocks are ranked based on the number of hedge funds holding stakes in them, highlighting their popularity among investors. The article also mentions the views of George Lee, the co-head of the Goldman Sachs Office of Applied Innovation, on the impact of AI on global growth, productivity, and geopolitics.
Investment
Neutral
DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH
DarioHealth Corp., a global leader in digital therapeutics, has announced it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time. CEO Erez Raphael and President Rick Anderson will host the call. DarioHealth is revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform.
growth-positive
New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications
DarioHealth Corp., a leader in the global digital therapeutics market, announced two new clinical studies at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024. The studies examined the impact of Darios integrated cardiometabolic solution on weight and diabetes management, with or without a GLP-1 medication. The first study showed a 6.38% reduction in weight for members with a baseline BMI of 30 and above and an overall reduction in blood glucose levels. The second study evaluated the effectiveness of Darios digital health solution in improving flu vaccine awareness and rates among its members.
Customers
Growth-Positive
DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE
DarioHealth Corp., a leader in the global digital health market, announced that its management will participate in the Cowen 44th Annual Healthcare Conference from March 4-6, 2024. CEO Erez Raphael and President Rick Anderson will participate in a fireside chat. A live webcast of the event will be available, with a replay accessible for 90 days after the event. DarioHealth is a digital health company that provides solutions for managing chronic conditions through a user-centric, multi-chronic condition digital therapeutics platform.
Management Changes
growth-positive
DarioHealth acquires fellow digital health firm Twill
DarioHealth, a digital health product maker for chronic conditions, has acquired mental health app maker Twill for $10 million in cash and about 10 million shares of common stock. The acquisition is expected to boost Darios revenue and accelerate its path to profitability. This comes as the digital health sector is expected to see increased merger and acquisition activity this year. Alongside the Twill acquisition, Dario announced it had raised $22.4 million in a private stock placement.
AcquisitionInvestment
Growth-Positive
Today's Schedule at The MicroCap Rodeo Winter Wrap Up Conference
On February 21, 2024, the CEOs of six MicroCap companies, namely La Rosa Holdings, Janover Inc., Base Carbon Inc., Data Storage Corp., SPG Sacks Parente Golf, and Dario Health Corp., will present at a virtual conference. The event, known as the MicroCap Rodeo Winter Wrap Up Conference, is designed for money managers and investors. Over a 4-day period, attendees will have the opportunity to learn about top stock ideas, meet with executive management teams from 15 MicroCap companies, and gain insights into key value drivers and potential trends for 2024.
Partners
growth-positive
Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions
DarioHealth Corp. has announced the acquisition of Twill, Inc., a leader in digital-led care. The acquisition is expected to double Darios pro forma revenues in 2023 and accelerate the companys path to profitability. The deal will also allow Dario to offer a more comprehensive digital offering for chronic conditions. The acquisition was financed through a $22.4 million equity financing. The combined company will have three of the top eight national health plans, multiple Fortune 100 employers, and several major pharmaceutical companies as customers.
AcquisitionInvestment
Growth-Positive
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 23, 2024
Diamond Equity Research, a leading small-capitalization equity research and conference provider, is set to host its Spotlight Investor Conference on January 23, 2024. The conference is open to all retail and institutional investors and will consist of a series of twenty-five-minute presentations by public company management teams, followed by a moderated question-and-answer session. The conference aims to provide investors with a unique opportunity to evaluate under-the-radar public companies and ask relevant questions directly to management.
CustomersPartners
growth-positive
Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET
Maxim Group LLC, a full-service investment banking, securities, and wealth management firm, and M-Vest, a digital community for issuers, investors, and thought leaders, are hosting the 2024 Healthcare IT Virtual Conference on January 24th and 25th. The conference will feature discussions with Healthcare IT companies about solutions to improve health outcomes, reduce healthcare costs, benefit healthcare providers, and improve customer experience. The conference will be live on M-Vest and will feature participation from various companies.
CustomersPartners
growth-negative
DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years
DarioHealth Corp.s share price has risen 38% in the past week, but long-term shareholders are still in the red as the share price has declined 86% over the past five years. Despite the companys revenue increasing by 34% per year over the last half decade, the market is concerned that profits wont come soon enough. The companys shareholders are down 58% for the year, underperforming the market which is up 21%. The companys long-term share price weakness could be a bad sign, but contrarian investors might want to research the stock in hope of a turnaround.
Customers
Growth-Positive
Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support
DarioHealth Corp., a global leader in digital health, has announced a new contract to provide its cardiometabolic solution to a regional union representing food industry workers. The solution will offer integrated support for employees living with diabetes, pre-diabetes, and weight management needs. The union joins a growing list of public and labor clients using Darios solution for personalized chronic condition management. The companys unique approach has proven to engage employees in healthier behaviors over time. The contract is expected to begin in the first quarter of 2024.
CustomersPartners
growth-positive
National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health
DarioHealth Corp. has announced a new contract to provide cardiometabolic and GLP-1 solutions to a national logistics company starting in January 2024. The company will deliver integrated support for employees living with diabetes, pre-diabetes, weight management, and hypertension. The solutions also include a tailored experience for employees taking a GLP-1 medication. Darios solutions have been proven to deliver long-term behavior change with and without a GLP-1 medication.
CustomersPartners
growth-positive
Is It Too Late To Consider Buying DarioHealth Corp. (NASDAQ:DRIO)?
DarioHealth Corp. has seen a significant price hike in the past few weeks, leading the NASDAQCM gainers. Despite this, the companys stock is still considered a bargain, with the intrinsic value for the stock being $2.16, while it is currently trading at $1.41. The companys earnings over the next few years are expected to increase by 26%, indicating a highly optimistic future. This is expected to lead to more robust cash flows, feeding into a higher share value. The companys prosperous future outlook isnt fully reflected in the current share price yet, making it a good time to invest.
Investment
growth-positive
Blue Shield of California's Award-Winning Wellvolution Now More Accessible for Spanish Speakers, Adds New Hypertension Offering
Blue Shield of California is expanding its digital health platform, Wellvolution, to better serve Spanish-speaking members and those with high blood pressure. The expansion includes the addition of Dario, a tech-enabled, at-home solution for hypertension. The platform was built in collaboration with Solera and currently has over 148,000 members enrolled. The expansion aims to close the care gap and increase access to lifestyle medicine in underserved communities. Wellvolution offers at least one Spanish language program for each health need covered under the platform.
CustomersPartnersExpand
Growth-Positive
Dario Contracts with New Employer for Cardiometabolic Solution
DarioHealth Corp., a leader in the global digital health market, has announced a new contract to provide its cardiometabolic solution to an employer, a national financial and business services company, starting in January 2024. The solution is an integrated approach for diabetes, pre-diabetes, weight management, and hypertension, along with support for employees taking GLP-1, or anti-obesity, medications. The companys platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for various chronic conditions.
CustomersPartners
growth-positive
New Research Sheds Light on Mediators of Improved Outcomes in Dario Users
DarioHealth Corp., a global digital health market leader, announced two new analyses presented by Sanofi U.S. The analyses showed improved clinical and economic outcomes in Dario users. The first analysis linked improved medication adherence with better clinical outcomes. The second analysis showed that more engaged Dario users were associated with a 10% reduction in all-cause healthcare resource use over 100 days. The analyses are part of Dario and Sanofis collaboration to set new standards in digital health research by analyzing real-world digital health data using the evidence generation principles of a pharmaceutical study.
CustomersPartners
growth-positive
Dario Publishes New Research Demonstrating that Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose
DarioHealth Corp., a global digital health market leader, announced new research presented at the Diabetes Technology Society 2023 Meeting. The research demonstrated the value of associating physical activity tracking with blood sugar tracking for people living with diabetes and pre-diabetes. Darios digital health solutions combine a clinically intelligent platform with highly personalized digital and human coaching. The study examined the blood glucose and walking data of 989 Dario users, showing significantly reduced blood glucose levels and increased step levels in the first four months of using Dario. The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.
CustomersPartners
Growth-Negative
DarioHealth Corp. (NASDAQ:DRIO) Analysts Just Trimmed Their Revenue Forecasts By 13%
Analysts have downgraded their revenue estimates for DarioHealth Corp., causing concern among shareholders. The consensus view of the business has become substantially more conservative, with analysts now predicting revenues of $31m in 2024, a 30% improvement in sales compared to the last 12 months. However, this is a decrease from previous forecasts of $35m. Losses are predicted to shrink by 26% to $1.64 per share. The consensus price target also fell by 9.2% to $7.10. Despite this, DarioHealths revenue growth is still expected to outpace the industry average.
growth-negative
DarioHealth Reports Third Quarter 2023 Financial and Operating Results
DarioHealth Corp. reported a decrease in total revenue for Q3 2023, with $3.52 million compared to $6.6 million in Q3 2022. The decrease was mainly due to lower commercial strategic partners revenues. However, the company also announced several positive developments, including an expanded relationship with Aetna and a new agreement with PlanSource. The company also plans to add 15 new customers to its platform in Q1 2024. Despite the decrease in revenue, the company ended the quarter with a strong financial position, with $44 million of cash and cash equivalents.
PartnersCustomers
growth-positive
Dario Launches Apple iPhone 15 Accessible Smart Blood Glucose Meter
DarioHealth Corp., a global leader in digital health, has announced the launch of a new smart blood sugar meter for Apple iPhone 15 users. The new device is designed to support ongoing engagement with new and existing members. The iPhone 15s USB-C charging port is a key element for real-time data capture in Darios smart blood glucose meter. The new meter offers instant connectivity for real-time blood sugar readings as part of the personalized Dario health management experience.
CustomersExpand
Neutral
DarioHealth to Report Third Quarter 2023 Results on Thursday, November 2nd
DarioHealth Corp., a global leader in the digital health market, has announced that it will release its financial results for the third quarter ended September 30, 2023, on Thursday, November 2, 2023. The company will host a conference call and webcast at 8:30 am Eastern Time. DarioHealth Corp. is a leading digital health company, revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. The companys solutions are offered globally to health plans, payers, self-insured employers, providers of care and consumers.
New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes
growth-positive
Dario Signs National Preferred Partner Agreement with a Top Five National Employee Benefits Consulting Firm
DarioHealth Corp. has announced a strategic partnership with a top five national employee benefits consulting firm. The partnership will see Dario become the preferred digital health and chronic condition solution partner for the firms national employer clients. The firm selected Dario for its ability to deliver meaningful engagement and improved clinical results at a lower cost than competitors. Darios suite of solutions combines innovative technologies and clinical support for chronic conditions into a single digital therapeutics platform.
Partners
Growth-Positive
DarioHealth to Host Investor Day on The Rise of Digital Health
DarioHealth Corp., a leader in the global digital health market, announced that it will host an in-person investor day in New York on October 17, 2023. The event will feature digital health industry leaders, including Arnaud Robert, former Head of Digital for Sanofi, Disney and Nike, and Felix Lee, U.S. Digital Healthcare Medical Head, Sanofi U.S. A Dario client and several members who utilize the Dario platform will share their experiences. Darios executive management team will provide a deep dive into the Companys product and market growth plans.
CustomersManagement Changes
growth-positive
DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 50% Below Their Intrinsic Value Estimate
The article discusses the valuation of DarioHealth Corp. using the 2 Stage Free Cash Flow to Equity model. The fair value estimate for DarioHealth is US$6.64, indicating that the company might be 50% undervalued at its current share price of US$3.34. The analyst price target for DarioHealth is US$7.82, which is 18% above the fair value estimate. The valuation is based on the companys future cash flows and their present value, using the Discounted Cash Flow (DCF) model. The article also mentions that the valuation is dependent on two assumptions - the discount rate and the cash flows.
Investment
growth-positive
Dario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs
DarioHealth Corp., a digital health company, has published research showing the positive impact of its digital behavioral health program on individuals with depression or anxiety. The study revealed that 63% of members using the Dario platform saw a significant reduction in depression and anxiety symptoms. The program uses a triage screener to assess individual mental health needs and recommend the right type of care. It offers self-guided programs designed to teach techniques for managing emotional health. Members can access digital resources such as coaching and breathing exercises at any time through the Dario app.
Customers
growth-positive
Dario Publishes New Research Demonstrating Greater Engagemenet and Improved Clinical Outcomes Sustainable for Two Years
DarioHealth Corp. presented new research at the ADCES23 Annual Conference, demonstrating the ability of its digital health solutions to improve health outcomes for users with diabetes over a two-year period. The research analyzed the data of 119,482 Dario members and showed a 29% improvement in engagement over two years. Users with high-risk diabetes experienced reductions in high-blood glucose readings and average glucose levels with increased engagement. The companys approach to outcome-based engagement was found to provide long-term benefits for members and partners. DarioHealth Corp. is a leading digital health company that offers personalized and dynamic interventions for chronic conditions through its user-centric platform.
Customers
growth-positive
Dario Partners with PlanSource to Offer Employers Easy Access to Proven Digital Health Solutions
DarioHealth Corp., a global leader in digital health, has announced a new agreement with PlanSource, a provider of cloud-based benefits administration and engagement technology. The agreement will allow Darios integrated digital health solutions to be offered to more than 5 million consumers. Darios solutions, which address conditions such as diabetes, hypertension, and behavioral health, will be included in employee health benefit plans as part of the PlanSource Partner Marketplace. The integration aims to create a seamless digital pathway for employees to engage in solutions that deliver improved, sustainable health outcomes.
PartnersExpand
growth-negative
Some DarioHealth Corp. (NASDAQ:DRIO) Analysts Just Made A Major Cut To Next Year's Estimates
Analysts have downgraded their revenue and earnings per share (EPS) forecasts for DarioHealth Corp., which could negatively impact the companys share price. The current consensus from five analysts covering DarioHealth is for revenues of $25m in 2023, a 7.2% reduction in sales over the past 12 months. Losses are expected to remain steady at around $2.18 per share. This is a change from previous expectations of $28m in revenue and $1.86 per share in losses. The consensus price target has also fallen 7.9% to $8.62.
Customers
growth-negative
DarioHealth Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
DarioHealths Q2 2023 results show a flat revenue of $6.15m and a net loss of $18.3m, which is a 5% increase from Q2 2022. The companys revenue exceeded analyst estimates by 2.3%, but its EPS fell short by 11%. Over the next three years, DarioHealths revenue is expected to grow by 43% annually, compared to a 7.8% growth forecast for the US Medical Equipment industry. However, the companys shares have fallen by 12% in the past week.
Customers
growth-positive
DarioHealth Reports Second Quarter 2023 Financial and Operating Results
DarioHealth Corp. reported its financial results for the second quarter of 2023. The company generated B2B recurring revenue growth for the tenth consecutive quarter, with revenues of $6.15 million. The companys gross profit margin improved to 33.7% of revenues for the second quarter of 2023, up from 18.4% for the same period in 2022. The company also reduced operating expenses by 13% in the second quarter of 2023 compared to the second quarter of 2022. DarioHealth launched a hypertension solution with a large regional health plan through a partnership with Solera and signed an expansion to that contract to include diabetes. The company also announced a contract with pharmacy benefit manager, MedOne, through Darios partnership with Sanofi.
CustomersPartnersManagement Changes
growth-positive
Dario Expands Partnership with Large Regional Health Plan
DarioHealth Corp. has announced the expansion of its agreement with a large regional health plan to provide digital health solutions to members living with diabetes, with the launch expected in Q1 2024. The health plan is adding Darios support for diabetes to complement the existing solution for hypertension. Darios diabetes solution has been proven to engage members in healthier behaviors, leading to lower care costs. The expansion of the agreement is expected to further validate Darios multi-condition strategy and its ability to expand its offerings with health plans over time.
CustomersExpand
Growth-Negative
The past five years for DarioHealth (NASDAQ:DRIO) investors has not been profitable
DarioHealth Corp. has seen its share price drop by 86% over the past five years, and by 40% in the last year. Despite this, the companys revenue has increased by 36% per year over the last five years, a rate that is higher than most other pre-profit companies. The market is likely concerned about when the company will start making a profit. The companys poor performance over the past year is part of a longer trend, with shareholders facing a total loss of 13% per year over five years.
Customers
Neutral
DarioHealth to Report Second Quarter 2023 Results on Thursday, August 10th
DarioHealth Corp., a leader in the global digital health market, has announced that it will release its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023. The company will host a conference call and webcast at 8:30 am Eastern Time. DarioHealth is a leading digital health company that provides a user-centric, multi-chronic condition digital therapeutics platform. The platform offers personalized and dynamic interventions driven by data analytics and one-on-one coaching for various conditions including diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
growth-positive
Dario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health Outcomes
DarioHealth Corp., a global digital health market leader, has announced a new program to provide tailored behavior change support for individuals using GLP-1s and other anti-obesity drugs. The program aims to improve overall health and provide valuable insights to Darios partners. The companys solution is designed to help people achieve their weight loss goals and impact multiple chronic conditions by focusing on changing underlying health behaviors. Members will have access to Darios new Medication Cabinet, a digital tool developed in collaboration with strategic partner, Sanofi US, to track medication adherence.
CustomersPartnersExpand
growth-positive
New Research Shows $5,077 in Medical Costs Savings for Dario Users
DarioHealth Corp., a leader in the global digital health market, announced a new analysis by Sanofi US demonstrating a significant reduction in the cost of care for Dario users compared to non-users living with Type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings for Dario users compared to non-users. The research data was presented by Sanofi at the American Diabetes Association 83rd Scientific Sessions. The study used an exact match and propensity-score matched non-user cohort that included access to usual care in a cohort of 2,445 Dario users and 7,334 matched non-users.
CustomersPartners
Growth-Positive
Dario Launches Agreement with Large Regional Health Plan and Announces Preliminary Results for Second Quarter of 2023 as well as Business Update
DarioHealth Corp. has announced a new agreement with a large regional health plan to provide digital health solutions to over 160,000 members with hypertension. The plan will launch in July 2023. Darios digital solution for hypertension is part of the companys cardiometabolic product suite. The company also announced preliminary unaudited revenue results for Q2 2023 of between $6.0 million and $6.15 million, driven by growth in its B2B sales channel. Strategic partnerships have yielded two notable wins for Dario this quarter, including contracts with MedOne Pharmacy Benefits Solution and the Plan attributed to Solera.
CustomersPartnersInvestment
growth-positive
New Research Demonstrates 2.3 Point Reduction in HbA1c for Dario Digital Health Users with Baseline HbA1c Greater Than 9 points
DarioHealth Corp. announced research presented at the American Diabetes Association 83rd Scientific Sessions demonstrating significant reductions in HbA1c for Dario users compared to non-users. The study was conducted by Sanofi U.S. under its strategic agreement with Dario. The research study is the second set of endpoints published as a result of Dario and Sanofis collaboration to set new standards in digital health research. The study used real-world patient data to analyze the impact of Dario on clinical, resource utilization, and financial outcomes. DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform.
Customers
growth-positive
Dario Announces Two New Full Suite Employer Contracts
DarioHealth Corp. has announced two new employer contracts for its integrated solutions, which are scheduled to launch in the second half of 2023. The contracts are with an educational organization in Tennessee and a non-profit in the New York metropolitan area. The demand for integrated multi-chronic solutions in the employer market is increasing as employers seek to reduce costs. DarioHealths digital health platform aims to make it easier for people to manage chronic health conditions. The company is excited to partner with the new clients and help them achieve their goals. DarioHealth is a leading digital health company that offers personalized and dynamic interventions for chronic conditions.
Customers
growth-positive
Dario Management to Participate in the Stifel 2023 Virtual Cross Sector Insight Conference
DarioHealth Corp. announced its participation in the Stifel 2023 Virtual Cross Sector Insight Conference. The companys president will give a presentation on their user-centric, multi-chronic condition digital therapeutics platform. DarioHealth offers personalized and dynamic interventions for various chronic conditions, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Their platform aims to disrupt the traditional episodic approach to healthcare and empower individuals to make sustainable behavior changes. DarioHealth provides its solutions globally to health plans, payers, employers, care providers, and consumers.
Partners
growth-positive
MedOne Launches Dario's Digital Health Solution to Help Members Improve Health with a Personalized Support
DarioHealth Corp. has announced a new agreement with MedOne Pharmacy Benefit Solutions to integrate Darios suite of digital health solutions into MedOnes digital diabetes solution. This partnership will enhance support services for diabetic patients and optimize treatment plans. The launch will be a phased rollout, starting with expansions into additional chronic disease states. The agreement originated from Darios collaboration with Sanofi US. DarioHealth Corp. is a leading digital health company that provides personalized and dynamic interventions for chronic conditions. MedOne is a pharmacy benefit manager focused on improving clinical outcomes and reducing costs for plan sponsors and members.
Partners
growth-positive
DarioHealth Corp. (NASDAQ:DRIO) Q1 2023 Earnings Call Transcript
DarioHealth Corp. reported its Q1 2023 earnings, beating expectations with an EPS of $0.45. The companys financial results show the success of its multiyear strategy, which includes a shift from direct-to-consumer to B2B and from a single point solution to an integrated multi-chronic condition platform. 70% of the companys revenues came from B2B. The company also announced significant new partnerships, including one with Amwell, one of the largest telehealth companies in the country. DarioHealths Q1 2023 revenue was $7.07 million, a sequential increase of 3.8% compared to Q4 2022.
CustomersPartners
growth-positive
DarioHealth Reports First Quarter Financial and Operating Results
DarioHealth Corp., a global digital health company, reported its financial results for Q1 2023. The company saw sequential quarterly growth in revenue to $7.07 million and improved its gross profit margin to 44.8%. It also reduced its net loss to $12.8 million in Q1 2023, compared to $15.9 million in Q1 2022. DarioHealth expanded its strategic relationships by signing with Amwell and the first account through its relationship with Sanofi. The company also announced the presentation of the first Sanofi of Dario data which showed a significant reduction in all-cause health care resource utilization, including a 23.5% reduction in hospitalizations.
CustomersPartnersManagement Changes
growth-positive
Sanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario users
DarioHealth Corp. announced the presentation of research at ISPOR 2023 demonstrating significant reductions in healthcare resource utilization for Dario users compared to non-users. The study conducted by Sanofi and presented at ISPOR demonstrates a statistically significant 9.3% reduction in all-cause Heath Care Resource Utilization (HCRU), including a 23.5% reduction in hospitalizations, in Dario users after 12 months. This impact of Darios digital diabetes solution across total health care utilization provides evidence that a whole-health approach to managing chronic conditions like diabetes can potentially reduce utilization rates that lead to potential cost savings.
Customers
growth-positive
DarioHealth Corp. (NASDAQ:DRIO) Might Not Be As Mispriced As It Looks
DarioHealth Corp.s price-to-sales (P/S) ratio of 3.4x is considered average for companies in the Medical Equipment industry in the United States. The companys revenues have been rising faster than most other companies, with a 35% gain to the companys top line in the last year and a total growth of 266% over the last three years. Analysts forecast that revenue will climb by 36% per annum during the next three years, outpacing the industrys expected expansion of 9.9% per annum. Despite this, DarioHealths P/S ratio remains similar to the industry, suggesting some shareholders are skeptical of the forecasts.
Customers
growth-positive
DarioHealth to Report First Quarter 2023 Results on Thursday, May 11th
DarioHealth Corp. will release its financial results for the first quarter of 2023 and host a conference call and webcast. The company is a leader in the global digital health market and offers a user-centric, multi-chronic condition digital therapeutics platform. Their platform provides personalized interventions and coaching for various chronic conditions. DarioHealths solutions are used globally by health plans, employers, care providers, and consumers. The company aims to disrupt the traditional episodic approach to healthcare and empower individuals to make sustainable behavior changes for better health. The conference call and webcast will provide an update on the companys performance and financial results.
Public Trading
Neutral
American Well (AMWL) Q1 2023 Earnings Call Transcript
The article is an announcement of Amwells Q1 2023 earnings call. Sue Dooley of Amwell investor relations, Amwells chairman and CEO, Dr. Ido Schoenberg, and CFO Bob Shepardson are mentioned as participants in the call.
None
growth-positive
DarioHealth Announces $14.3 Million Private Placement
DarioHealth Corp. has announced a $14.3 million private placement of convertible preferred stock, priced at the market under Nasdaq rules. The company has also refinanced its existing credit facility, resulting in a proforma cash balance of $60 million. These actions are expected to extend the companys cash runway through late 2025. The private placement is set to close on or before May 3, 2023. The financing will support the companys long-term growth strategy focused on high-margin, highly scalable B2B customer channels. The refinancing is expected to save the company approximately $500,000 in monthly amortization payments. DarioHealth Corp. is a leading digital health company that provides personalized and dynamic interventions for chronic conditions.
Investment
growth-positive
Digital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer
DarioHealth Corp. has announced the appointment of Eitan Shay as Chief Product Officer and Arnaud Robert as Strategic Advisor to the CEO. These appointments strengthen Darios ability to scale its digital therapeutics platform and meet growing market demand. The company aims to enhance and scale its intelligent platform to drive long-term success. DarioHealth is a leading digital therapeutics company that offers personalized and dynamic interventions for chronic conditions. The company provides its solutions globally to health plans, employers, care providers, and consumers. In addition to the appointments, Eitan Shay has been granted stock options to purchase shares of the companys common stock.
Management Changes
growth-positive
Dario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager
DarioHealth Corp. has announced a new contract with a leading nationwide Pharmacy Benefits Manager (PBM) to provide its digital therapeutics solutions, starting with the diabetes solution, to employer clients. The contract is the result of Darios strategic partnership with Sanofi U.S. and represents a major milestone achievement. The partnership with the PBM is expected to generate revenue in the second quarter of 2023 and grow significantly throughout the year. Dario is focused on building partnerships with market-leading healthcare companies to accelerate the adoption of its solutions. The company offers a user-centric, multi-chronic condition platform that delivers personalized interventions for chronic conditions.
PartnersCustomers
growth-positive
Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution
DarioHealth Corp. has announced a strategic partnership with Amwell to deliver its cardiometabolic solution to Amwell customers. The partnership aims to accelerate the adoption of Darios solutions by making them available to existing Amwell customers. Darios solution will be integrated into Amwells digital care delivery enablement platform, providing members with access to personalized digital solutions for managing cardiometabolic health concerns. The partnership aligns with the market demand for more condition solutions from fewer vendors and lower costs for innovative digital health. The integration is expected to begin in the second half of 2023.
Partners
growth-positive
Dario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine Learning
DarioHealth Corp. has announced new research investigating the personalized efficacy of digital therapeutics for pain management. The research focuses on the reduction of back pain for users in a digital posture training program by adapting machine learning models. The study analyzed data from 3,610 users who experienced significant reductions in back pain after using the posture training program. The results offer a framework for understanding the effectiveness of digital therapeutics in managing pain. DarioHealth aims to deliver personalized user journeys and optimize user care through the use of biofeedback data and machine learning. The research was conducted in partnership with the Integrative Pain Laboratory at the University of Haifa.
Customers
The DarioHealth Corp. (NASDAQ:DRIO) Annual Results Are Out And Analysts Have Published New Forecasts
DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results
growth-positive
DarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9th
DarioHealth Corp. will release its financial results for the fourth quarter and year ended December 31, 2022. The company will host a conference call and webcast to discuss the results. DarioHealth is a leader in the global digital therapeutics market, providing personalized and dynamic interventions for chronic conditions through its user-centric platform. The company aims to revolutionize how people manage their health by offering continuous and customized care. DarioHealths solutions are used globally by health plans, employers, care providers, and consumers. The conference call and webcast will be hosted by the CEO, President, and CFO of DarioHealth.
InvestmentManagement Changes
growth-positive
What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?
DarioHealth has partnered with Dexcom to integrate Darios multi-chronic condition platform with Dexcoms continuous glucose monitoring (CGM) technology. The collaboration builds on Darios existing partnership with Sanofi US and aims to establish an ecosystem of dedicated technology partners and digital therapeutics solutions. The article highlights the markets oversight of DarioHealths revolutionization in healthcare management and mentions the companys strategic partnerships with Sanofi, Virgin Pulse, Solera, and Alliant. DarioHealths preliminary results show successful transformation from B2C to B2B sales channels, with expected total revenue of $27.5 million for the year. Dexcom and Sanofi also reported strong financial results. The event described in the article occurred on February 28, 2023.
PartnersCustomers
growth-positive
New Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference
DarioHealth Corp. announced two new clinical studies demonstrating the impact of targeted coaching interventions in their digital-first chronic care solution. The studies showed improved clinical outcomes in users with Type 2 diabetes and the ability to reduce hypoglycemic events in older adults. The research highlighted the importance of incorporating the optimal mix of human and digital coaching to drive engagement and achieve improved clinical outcomes. The use of coaching in a digital health solution was found to have a positive impact on behaviors and outcomes. The studies provide valuable data to support the scaling of digital health solutions in effective and affordable ways.
Customers
growth-positive
DarioHealth to Participate in the Cowen 43rd Annual Healthcare Conference
DarioHealth Corp. announces its participation in the Cowen 43nd Annual Healthcare Conference. The companys CEO and President will be participating in a fireside chat during the event. A live webcast of the chat will be available, with a replay available afterwards. DarioHealth Corp. is a global digital therapeutics company that offers comprehensive solutions for managing chronic conditions. Their next-generation, AI-powered platform provides personalized experiences and interventions to help individuals improve their health. The company operates at the intersection of life sciences, behavioral science, and software technology.
PartnersManagement Changes
growth-positive
DarioHealth Announces Two New Employer Contracts
DarioHealth Corp. has announced two new employer contracts, including one for the full suite of integrated solutions. The contracts demonstrate the continued demand for Darios digital chronic condition management solutions. The companys platform offers personalized and dynamic interventions for various chronic conditions. The new accounts are scheduled to launch in late 2022 and early 2023. DarioHealth is a leader in the global digital therapeutics market.
Customers
growth-positive
DarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility with OrbiMed
DarioHealth Corp. has closed a senior secured term loan facility of up to $50 million with OrbiMed, providing non-dilutive capital to fund the development of its digital therapeutics platform and accelerate its adoption in the chronic disease management market. The facility is structured with a $25 million loan at closing and an additional $25 million available for a future draw. The company believes that with this funding, along with its cash and cash equivalents, it potentially has access to more than $100 million in capital, allowing it to invest in growing its business-to-business market segment and pursue its business plan for multiple years without the need for further capital raises.
Investment
growth-positive
DarioHealth Reports Fourth Quarter and Full Year 2021 Results and Operational Highlights
DarioHealth Corp., a global leader in digital therapeutics, reported its financial results for Q4 and full year 2021, highlighting significant growth in its B2B business. The companys total revenue increased by 171% from $7.6 million in 2020 to $20.5 million in 2021, largely due to acquisitions and increasing sales in the B2B channel. The company also signed a multi-year agreement with healthcare company Sanofi to accelerate the adoption of Darios solution in the payer market. DarioHealth raised $40 million through a registered direct offering in March 2022.
CustomersPartnersAcquisitionInvestment
growth-positive
DarioHealth Enters into Strategic Agreement with Sanofi U.S.
DarioHealth Corp. has entered into a strategic agreement with Sanofi U.S. The multi-year, $30 million-dollar agreement will help accelerate commercial adoption of Darios digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution and developing new solutions leveraging the Dario platform. Sanofi selected Dario as the solution of choice for its U.S. commercial clients. The collaboration aims to expand into the digital health market and support Sanofis goal of expanding into digital health therapies for chronic conditions.
PartnersExpand
growth-positive
DarioHealth Enters Agreement to Acquire Physimax, a Leading Provider of Validated Computer Vision for Musculoskeletal Health
DarioHealth Corp. has announced its agreement to purchase certain assets of Physimax Technologies Ltd., a leading provider of computer vision technology for Musculoskeletal functional screening. The acquisition will strengthen DarioHealths ability to scale effective treatments for musculoskeletal health and reduce the burden on human support. In consideration for the acquisition, DarioHealth will issue shares of its common stock and make a cash payment of $500,000, as well as assume certain liabilities. The closing of the acquisition is subject to customary closing conditions and the approval of the Israeli Innovation Authority.
Acquisition
growth-positive
DarioHealth Gathers Momentum in the Provider Market with Two New Contracts for Remote Patient Monitoring Services
DarioHealth Corp. has entered into contracts with two regional providers in Hawaii and Georgia for its Remote Patient Monitoring (RPM) services. The contracts expand Darios provider footprint and will provide RPM services for patients with diabetes and hypertension. Darios ability to engage and retain patients on its platform was a decisive factor in securing the partnerships. The company supports over 197,000 members on its digital therapeutics platform and operates in the Midwest, Southeast, and Southwest. DarioHealth is a leading global digital therapeutics company that offers comprehensive solutions for managing chronic conditions.
Partners
growth-positive
DarioHealth joins Virgin Pulse partner network
DarioHealth has partnered with Virgin Pulse to offer its digital therapeutic and health solutions to employers and health plans worldwide. DarioHealth provides comprehensive digital therapeutics solutions for chronic conditions, and its benefits will now be available through Virgin Pulses Homebase for Health® solution. The partnership aims to improve member health outcomes and decrease healthcare costs by leveraging DarioHealths solutions. Virgin Pulse rewards members for utilizing DarioHealths services, such as logging health data and setting health goals. The partnership expands the visibility of DarioHealths solutions and aligns with Virgin Pulses commitment to wellbeing.
Partners
growth-positive
DarioHealth Unveils its Digital Musculoskeletal Solution Dario Move at HLTH 2021
DarioHealth Corp. has announced the launch of Dario Move, a new digital physical therapy solution for managing musculoskeletal conditions. The solution is being unveiled at the HLTH 2021 conference. With the addition of Dario Move, Darios suite of products now supports comprehensive chronic condition management across diabetes, behavioral health, and metabolic health needs. The cost of care for musculoskeletal health has increased significantly, making it one of the costliest conditions for employers. Dario Move aims to improve access to care by providing digital physical therapy in the home, with personalized exercises and real-time support. The integration of Dario Move strengthens Darios platform and its ability to deliver results and value for partners.
CustomersPartners
growth-positive
DarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner
DarioHealth Corp. has been selected by PeopleOne Health as the digital behavioral health solution for patients. This represents Darios growth in the provider market. PeopleOne Health will integrate Darios solution to address mental health needs for its consumer and employer partner populations. The solution uses AI-driven screening and digital tools to provide seamless care. Darios President believes the agreement reflects the value of their digital behavioral health solution in point-of-care settings. DarioHealth Corp. is a global digital therapeutics company that offers comprehensive solutions for chronic conditions.
Partners
growth-positive
DarioHealth Announces Closing of wayForward Acquisition
DarioHealth Corp. has announced the completion of its acquisition of PsyInnovations, Inc. The acquisition was made through the merger of PsyInnovations into DarioHealths subsidiary, WF Merger Sub, Inc. The total consideration for the merger includes $6.0 million in cash and up to $24.0 million in shares of DarioHealth common stock. The merger will allow DarioHealth to expand its digital therapeutics offerings in the behavioral health sector. The founders of PsyInnovations, Mr. Ritvik Singh and Dr. Navya Singh, will join DarioHealth as General Manager, Head of Behavioral Health, and Chief Behavioral Science Officer, respectively. DarioHealth is a global digital therapeutics company that provides personalized solutions for managing chronic conditions.
Acquisition
growth-positive
DarioHealth expands mental health foothold with wayForward acquisition
DarioHealth has acquired digital mental health company wayForward for $30 million. The acquisition includes the purchase of PsyInnovations, the creator of wayForward. DarioHealth aims to expand its chronic care coverage to include mental health. The platform offers an AI triage and screening tool, cognitive behavioral therapy, self-directed care, expert coaching, and access to in-person and telehealth visits. The shortage of mental health professionals in the U.S. and the increased need for mental healthcare during the pandemic have driven the demand for technology-driven solutions. DarioHealth has been actively expanding its scope in recent years and sees behavioral health as a top priority. The acquisition of wayForward aligns with the companys goal of providing a suite of best-in-class solutions for multiple chronic conditions on one platform.
Partners
growth-positive
Digital therapeutics co Dario raises $70m, buys Upright
DarioHealth Corp. is acquiring Upright Technologies Ltd. for $31 million in a stock transaction. The acquisition adds Uprights musculoskeletal solution to Darios digital therapeutic platform. Dario has also raised $70 million through a private placement of its common stock. The company has recently signed major strategic deals and its share price has risen 200%. Dario intends to use the proceeds for general corporate purposes. Upright CEO Oded Cohen will serve as Darios General Manager of MSK product and join Darios Board of Directors.
Partners
growth-positive
DarioHealth Announces Hiring of Leading Digital Health Innovator as Senior Vice President of Employer Sales
DarioHealth Corp. has appointed Chris Chan as Senior Vice President of Employer Sales. Chan will be responsible for leading growth initiatives in the self-insured employer market. His appointment strengthens DarioHealths Employer Market team. DarioHealth is a global digital therapeutics company that offers solutions for individuals with chronic conditions. The company aims to improve health outcomes through evidence-based interventions driven by connected devices, data, software, and coaching. DarioHealths MyDario mobile app is highly rated and widely used. The company is expanding into new chronic conditions and geographic markets.
Management Changes
growth-positive
Diabetes and Behavioral Health Global Experts Join DarioHealth Scientific Advisory Board Expanding Innovation Leadership in Digital Therapeutics for Chronic Care
DarioHealth Corp. announced the addition of Dr. Marilyn Ritholz and Dr. David Horwitz to its Scientific Advisory Board (SAB), which will help guide the development of its technology roadmap and strengthen its offering for the management of chronic conditions. The SAB members are recognized for their expertise in diabetes, metabolism, and behavioral health. The addition of the SAB is expected to promote increased stakeholder awareness and deeper market penetration of Darios platform, as well as improve the health of individuals. DarioHealth is a leading global digital therapeutics company that delivers evidence-based interventions for chronic conditions through connected devices, data, software, and coaching.
Partners
growth-positive
DarioHealth Appoints Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships
DarioHealth Corp. has appointed Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships. This appointment is expected to strengthen the companys commercial team and accelerate its growth in the digital therapeutics market. Claudia Rimerman Kraut has a strong background in benefits, partnerships, and digital health, having previously worked at Omada Health, American Well, United Health, AIG, Humana, and MetLife. DarioHealths collaborative and open-architecture model, along with its evidence-based programs and personalized user experience, are valued by benefits consultants and will give the company a competitive advantage. DarioHealth is a leading global digital therapeutics company that offers solutions for chronic conditions like diabetes and hypertension.
Partners
growth-positive
DarioHealth's Digital Therapeutics Solution Selected as Employee Health Benefit by Self-Insured, Fortune 500 Subsidiary
DarioHealth Corp. has entered into an agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of a U.S. based Fortune 500 technology and engineering company. This partnership represents a significant step forward in DarioHealths transformation to a B2B2C focused provider of digital therapeutics solutions. The agreement includes Darios diabetes and hypertension solution and is expected to begin enrolling members in January 2021. The partnership with Vitality Group aims to help employees manage chronic health issues and achieve better, healthier outcomes. DarioHealth is a leading global digital therapeutics company that delivers evidence-based interventions driven by connected devices, data, software, and coaching.
Partners
growth-positive
DarioHealth Announces Agreement with Presbyterian Medical Services for Remote Patient Monitoring
DarioHealth Corp. has entered into an agreement to provide its remote patient monitoring solution to Presbyterian Medical Services, effective January 1, 2021. The partnership will give patients living with chronic conditions access to Darios AI-powered digital therapeutics tools and quality care. The agreement was the result of a rigorous request for proposal process. Financial terms were not disclosed.
Partners
growth-positive
DarioHealth's Digital Therapeutics Solution Selected as Employee Health Benefit by Self-Insured, Fortune 500 Company
DarioHealth Corp. has signed a contract to provide its digital therapeutics solution to eligible employees of a U.S.-based Fortune 500 technology company. The contract represents an important milestone in DarioHealths strategic shift toward the business-to-business-to-consumer (B2B2C) market. The company believes that this contract validates the competitive strength of its digital chronic care solution. DarioHealth offers one of the highest-rated diabetes and hypertension solutions on the market. The company aims to improve the health of people with chronic conditions by delivering evidence-based interventions driven by connected devices, data, software, and coaching.
Customers
growth-positive
New DarioHealth Study Shows Increased Digital Therapeutics Engagement Leads to Marked Reduction in Blood Glucose, Lower High Readings among Type 2 Diabetic Seniors
DarioHealth Corp. presented results from a new clinical study at the 20th Annual Diabetes Technology Society Meeting. The study showed a marked reduction in high blood glucose readings and average blood glucose readings in adults over the age of 65 using Darios digital therapeutics platform. The study demonstrated that the positive clinical outcomes for older adults using the Dario platform were comparable, and in some cases more favorable, than those of younger adults. The results suggest that the Dario platform can significantly reduce high blood glucose ratios and improve clinical outcomes for older individuals with diabetes. DarioHealth is a leading global digital therapeutics company that empowers individuals to manage their chronic conditions through evidence-based interventions and coaching.
Customers
growth-positive
DarioHealth Announces Inclusion of its Digital Therapeutics Platform in Vitality Group's New Gateway Flex Offering
DarioHealth Corp. has been chosen by Vitality Group to include its digital therapeutics solutions in Vitalitys new Gateway Flex offering. This partnership reinforces DarioHealths position as a partner of choice and allows the company to scale and integrate into an increasingly complex ecosystem of employer benefit providers. The Gateway Flex offering provides employers with simplicity, flexibility, and cost-effectiveness in personalizing the healthcare experience for their employees. DarioHealth and Vitality Group entered into a partnership in March 2020 to penetrate the self-insured employer market. Vitality Group is a leading wellness company with partnerships with insurers and employers worldwide. DarioHealth Corp. is a global digital therapeutics company focused on helping people with chronic conditions manage their health.
Partners
growth-positive
DarioHealth and HMC HealthWorks Announce Partnership Agreement
DarioHealth Corp. has entered into a sales and distribution partnership with HMC HealthWorks. HMC will incorporate DarioHealths digital therapeutics solution into its comprehensive care management programs. The partnership expands the distribution of DarioHealths solutions and allows them to build a pipeline within HMCs client base. The agreement is seen as validation of DarioHealths progress in becoming a leading provider of digital therapeutics solutions.
Partners
growth-positive
DarioHealth Announces $28.6 Million Private Placement
DarioHealth Corp. has closed a private placement transaction, raising approximately $28.6 million in gross proceeds. The funds will be used to support the companys long-term strategic operating plan, focusing on the business-to-business-to-consumer channel. This channel is characterized by lower customer acquisition costs, higher margins, and recurring revenues. The company aims to secure contracts with health plans, self-insured employers, and providers. The financing round included existing shareholder Nantahala Capital Management and new investors such as Manchester Management Company, Soleus Capital Management, and leading Israeli institutional investors. The transaction closed on July 31, 2020.
InvestmentExpand
growth-positive
DarioHealth says studies show effectiveness of its smart diabetes monitor
DarioHealth Corp., a New York-based firm, has developed a smart device to monitor glucose levels in the blood. Two new studies show that users of its digital device saw improvements in their blood sugar level and blood pressure. The companys mobile monitor, developed in Israel, helps patients manage their diabetes on the go by providing them an all-in-one blood glucose meter. The device connects to smartphones or tablets and transmits the information to the DarioHealth app, which can be sent to doctors and healthcare systems. The app also provides personalized coaching and real-time emergency alerts. DarioHealth is expanding its solutions to include other chronic conditions. The studies were presented at the American Diabetes Associations 80th Scientific Sessions.
Customers
growth-positive
DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines
DarioHealth Corp. has announced that the U.S. Food and Drug Administration (FDA) has recognized the use of Darios smartphone-connected blood glucose metering device by patients with diabetes who are hospitalized due to COVID-19. This recognition allows hospitals to allow patients to self-test using Darios device or issue them a device upon admission. The lifting of restrictions on blood glucose monitoring in hospitals is seen as a positive development for healthcare workers and patients, as it reduces contact and potential exposure to the virus. DarioHealth is a global digital health company that provides mobile health solutions for chronic disease management.
Customers
growth-positive
DarioHealth poaches former Catasys execs, launches behavioral health coaching
DarioHealth, a company that helps patients manage diabetes and hypertension, has rolled out a new mental health coaching service for its users. The service aims to help users manage stress, anxiety, and loneliness. DarioHealth had been planning the service prior to the Covid-19 pandemic, but the pandemic accelerated its rollout. The company has added a feature to connect users with behavioral health coaches and aims to integrate behavioral health services into its main app. DarioHealth is not the only company focusing on mental health services for patients with chronic conditions, as other companies like Omada and Livongo have also made similar moves.
CustomersPartners
growth-positive
DarioHealth partners with MediOrbis to bring telemedicine to its mobile disease management platform
DarioHealth has integrated with MediOrbis MySpecialistMD network to provide telemedicine services to chronic disease patients using its mobile glucose management system. The virtual services offered through the app include primary and acute care, chronic disease management, and specialty consultations. The partnership was driven by the increased risk of complications from COVID-19 for those with chronic illnesses. DarioHealth sees the integration as a value add for its 50,000 users. The COVID-19 pandemic has prompted many healthcare stakeholders to embrace telehealth, leading to opportunities for digital health platforms to expand.
Customers
growth-positive
DarioHealth raises $21.3m in private placement
DarioHealth Corp. has closed a private placement of convertible preferred stock, raising $21.3 million. The funding will be used to accelerate the companys B2B initiatives, support D2C sales and marketing, expand the US sales and marketing infrastructure, and increase the breadth of chronic conditions addressed by DarioHealths digital therapeutics platform.
InvestmentExpand
growth-positive
Walmart.com now selling Israeli diabetes management system
Walmart.com is now distributing the DarioHealth digital diabetes management system. The partnership aims to offer Walmarts consumers a complete digital solution to manage diabetes, hypertension, nutrition, and exercise. DarioHealths diabetes app is highly rated and has thousands of reviews on the Apple store. DarioHealth utilizes big data for chronic disease data management, allowing individuals to personalize their diabetes management. Walmart.com is the ecommerce arm of Walmart, the worlds largest retailer.
Customers
growth-positive
DarioHealth targets physical retail with its mobile-friendly diabetes management platform
DarioHealth is bringing its Membership-in-a-Box glucose management system to physical retail chains like Best Buy. The offering includes a connected blood glucose meter, test strips, lancets, and a three-month membership with digital management and coaching features. The starter kit is priced at $69.99. By expanding to physical stores, DarioHealth aims to reach a new slice of the market that may not actively seek digital diabetes support. The company has also made an arrangement with supermarket chain Giant Eagle. This move aligns with DarioHealths software-as-a-service business model, which has seen 75% of memberships renewed by users.
CustomersPartners
growth-positive
NHS-Backed DigitalHealth.London Partners With Medtech Company DarioHealth
DarioHealth Corp., a diabetes monitoring company, has partnered with DigitalHealth.London as part of the U.K. Israel Dangoor Health Initiative. The partnership allows NHS patients to access Darios digital therapeutics technology for diabetes management. Financial details were not disclosed.
CustomersPartners
growth-positive
The American Diabetes Association Partners With Diabetes Monitoring Company Dario
DarioHealth Corp., a diabetes monitoring company, has announced a partnership with the American Diabetes Association. The partnership aims to advance the associations mission to prevent and cure diabetes. Dario develops a diabetes monitoring device that allows users to test and track their blood-glucose levels in real time using a smartphone. The device has received regulatory approval in the U.S., Europe, Australia, and Canada. As part of the partnership, Dario will sponsor the Associations 2019 Step Out: New York City fundraising event in September.
Partners
growth-positive
DarioⓇ Becomes a Member of the Digital Therapeutics Alliance
DarioHealth Corp. has become a member of the Digital Therapeutics Alliance (DTA), demonstrating its commitment to integrating and utilizing digital therapeutics in the healthcare industry. Dario offers a mobile application that engages and educates users on various health topics, along with a platform for healthcare professionals to access patient data and provide recommendations. The company aims to slow the progression of chronic conditions through data-driven interventions. By joining the DTA, Dario aims to contribute to improving the overall healthcare industry and creating a better experience for patients and clinicians. The Digital Therapeutics Alliance is a non-profit trade association focused on the adoption and integration of clinically-validated digital therapeutics in healthcare.
Partners
growth-positive
Dario® Elevates Digital Therapeutics Capabilities by Further Enhancing Patient Experience
DarioHealth Corp. has launched a new version of its Dario system and DarioEngage platform, aiming to drive user engagement, lower barriers to behavioral change, and streamline the user experience. The enhancements include a more intuitive and personalized experience, robust customer engagement management functions, and improved personalization. The system also features graphic intuitive tools, progress alerts, educational content, troubleshooting, and enhanced in-app reports. The updates aim to improve the user experience for both patients and healthcare providers. DarioHealth Corp. is a leading global digital therapeutics company that empowers individuals to manage their health through evidence-based interventions and coaching.
Customers
growth-positive
DarioHealth Signs Leading Functional Medicine Clinic to DarioEngage™ Remote Digital Diabetes Platform
DarioHealth Corp. has announced an agreement with Auer Integrative Healths Functional Medicine and Chiropractic to use its DarioEngage healthcare provider platform for remotely monitoring and managing patients with diabetes and pre-diabetes. Auer Integrative will adopt Darios Per Engaged Member, Per Month (PEMPM) business model. This partnership allows DarioHealth to scale up its growth and deliver better clinical outcomes for patients. The platform provides real-time access to patient data, such as blood glucose levels, nutrition, and exercise, allowing healthcare professionals to engage with patients more effectively and frequently. DarioHealth aims to reduce the costs of chronic illness and improve clinical outcomes. The clinic will also stock Dario starter kits and products for patients who opt out of remote monitoring.
Partners
growth-positive
DarioHealth Partners With Glytec on Outpatient Diabetes Management
DarioHealth Corp. has announced a joint marketing agreement with Glytec, a market leader in insulin titration solutions. The agreement allows DarioHealths smart glucose meter to transmit information to Glytecs Glucommander Outpatient software. This enables virtual insulin titration for outpatients with diabetes. The partnership aims to provide personalized insulin dose recommendations by utilizing blood glucose data from Darios monitoring system. The collaboration is expected to enhance the effectiveness of diabetes management and improve A1c levels. DarioHealth Corp. is a global digital therapeutics company, while Glytec is a pioneer of personalized digital therapeutics for insulin optimization.
Partners
growth-positive
DarioHealth Granted License by Health Canada to Sell Dario Smart Glucose Meters for Lightning® Connector Enabled iPhones
DarioHealth Corp. has received a license from Health Canada to sell its Dario Blood Glucose Monitoring System for Lightning power connector-enabled iPhone smart mobile devices. This expands DarioHealths addressable Canadian market to include the entire iPhone user base. The license allows iPhone users in Canada to access DarioHealths digital diabetes products and lifestyle management app features. The companys CEO, Erez Raphael, expressed the importance of this initiative and the opportunity it presents for new users and existing Canadian users who have upgraded their iPhones. DarioHealth is a leading global Digital Therapeutics (DTx) company that focuses on revolutionizing the way people manage their health across chronic conditions.
Customers
growth-positive
DarioHealth Signs National Distribution Deal in the U.S. With Better Living Now for Its Digital Health Products
DarioHealth Corp. has signed a distribution agreement with Better Living Now (BLN) for the distribution of its Dario Blood Glucose Monitoring System and DarioEngage digital health platform. BLN will purchase DarioHealths products for distribution to its customers and offer a diabetes management program including coaching through DarioEngage. This partnership is expected to significantly increase DarioHealths market penetration.
PartnersCustomers
growth-positive
DarioHealth's Diabetes Digital Health Solution Now Available at Best Buy
DarioHealth Corp. announced that the Dario Blood Glucose Monitor has been included in Best Buys portfolio of digital healthcare services and products. The partnership with Best Buy allows DarioHealth to expand its collaboration and offer remote patient monitoring and other service-based offerings. DarioHealth is a leading global digital health company that provides mobile health solutions for chronic disease data management.
Partners
growth-positive
DarioHealth Launches Integrated Diabetes Digital Health Solution Including Version 4.1 of Its Award-winning Dario App and DarioEngage Patient Coaching Platform
DarioHealth Corp. has launched version 4.1 of its Dario App for the Dario Blood Glucose Monitoring System. The app is now fully integrated with the DarioEngage patient management and coaching platform, creating a unified diabetes digital health platform. New features include enhanced in-app acquisition capabilities, one-click scheduling for healthcare providers and patients, and a holistic integrated solution. The company believes this is the most advanced solution of its kind. The Dario Blood Glucose Monitoring System has shown positive clinical outcomes and average cost savings of $230 per patient, per month. DarioHealth Corp. is a leading global digital health company.
CustomersPartners
growth-positive
DarioHealth's Digital Health Blood Glucose Monitoring System Compatible With New iPhone XS and XS Max
DarioHealth Corp. announced that its Dario LC Blood Glucose Monitoring System is compatible with the iPhone XS and iPhone XS Max, expanding its market reach and increasing the value of its DarioEngage platform. The company aims to improve the health and wellbeing of people with chronic conditions by providing mobile health solutions. The Dario system can now be used on all major mobile phone platforms. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event.
Customers
growth-positive
DarioHealth Appoints Glen D. Moller, Healthcare Executive, Investor and Former CEO of ArroHealth, to Its Board of Directors
DarioHealth Corp. has announced the appointment of Glen Moller to its Board of Directors. Moller is a highly regarded healthcare executive with a background in managed care and technology-enabled health services. He has held leadership positions in major healthcare companies in the U.S. and is currently an Operating Partner at Frazier Healthcare Partners. DarioHealth believes that Mollers expertise and network will support the rollout of its digital health platform to healthcare providers and payers. Moller commented that DarioHealths data-based, patient-friendly platform has the potential to significantly lower costs for providers. DarioHealth is a leading global digital health company that provides mobile health and big data solutions.
Management Changes
growth-positive
DarioHealth Closes on $10,345,000 Through Private Placement Offering
DarioHealth Corp. has closed a private placement offering, raising $10,345,000 in total. The offering included the sale of shares of the companys common stock and newly designated Series D convertible preferred stock. The funds raised will support the companys path of accelerated growth towards profitability. DarioHealth is a leading global digital health company that provides mobile health and big data solutions. The company has seen 14 consecutive quarters of increasing revenues and 84% year-over-year revenue growth from 2016 to 2017. The private placement was managed by the company with the assistance of A.G.P./Alliance Global Partners as the placement agent.
Investment
growth-positive
DarioHealth Chosen by Attain Health for Pilot Study to Improve Cystic Fibrosis Related Diabetes Management
DarioHealth Corp. has entered into an agreement with Attain Health to pilot the DarioEngage platform for the management of cystic fibrosis related diabetes. The focus of the study is to partner with clients and their care teams to more efficiently manage hyperglycemia in people living with cystic fibrosis. Attain Health has committed to the pilot by paying for access to the DarioEngage Dashboard. Attain Health and DarioHealth plan to present preliminary findings from the pilot study at the North American Cystic Fibrosis Conference. Final results are expected in December 2018.
Partners
growth-positive
DarioHealth Provides Update on Recently Launched iPhone 7, 8 and X Smart Glucose Meter in the U.S. Following FDA Clearance
DarioHealth Corp. has experienced a successful launch of its iPhone-compatible Blood Glucose Monitoring System following FDA clearance. The company has witnessed positive market acceptance for its Lightning-enabled version of the system, which is compatible with iPhone 7, 8, and X. The substantial installed base of these iPhone models in the U.S. presents a significant market opportunity for DarioHealth. The company plans to continue developing and expanding its product offering, as well as expanding its business-to-business and business-to-consumer channels. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event.
Customers
http://digitalhealthage.com/dariohealth-gains-fda-approval-for-lightning-connected-blood-glucose-system/
growth-positive
DarioHealth Launches Customer Hotline to Pre-Order Its Apple iPhone Lightning-Compatible Glucose Monitor in the U.S.
DarioHealth Corp. announces the pre-order option for its Lightning-enabled version of the Dario Blood Glucose Monitoring System in the U.S. The company expects to ship the first iPhone Lightning-compatible glucose monitor in the coming weeks. This product launch aims to simplify diabetes management and cater to most people with diabetes in the U.S. who use smartphones. DarioHealth has been marketing the product exclusively for Apple iOS and certain Android devices, and with this announcement, it expands its U.S. marketing reach.
CustomersExpand
growth-positive
Blood Glucose Monitor Adapts to Lightning Headphone Jacks
DarioHealth Corp. has received FDA pre-market notification clearance for its Lightning-enabled version of the Dario Blood Glucose Monitoring System, allowing the use of the Dario app on iPhone 7, 8, and X. This opens up a significant market opportunity in the U.S. and enables past users who upgraded to these iPhones to renew their Dario experience. The FDA clearance is a big breakthrough for DarioHealth and paves the way for wide-scale expansion in the U.S. market. The company has been marketing the product exclusively for Apple iOS and certain Android devices since 2015 and 2017 respectively.
Customers
growth-positive
DarioHealth Reports Fourth Quarter and Year End 2017 Results
DarioHealth Corp., a global digital health company, has reported its financial results for Q4 and the full year of 2017. The company saw record revenues of $1.6m in Q4, an 88% increase compared to Q4 2016. The company also reported a gross profit of $569,000, a 188% increase compared to Q4 2016. For the full year, the company reported record revenues of $5.2m, an 84% increase compared to 2016. The company also launched into a new market, Germany, and received three additional regulatory clearances. In Q1 2018, DarioHealth raised approximately $6.6m.
Investment
growth-positive
DarioHealth simplifies diabetes with managed care platform - BioTuesdays
DarioHealth is a diabetes managed care platform that offers real-time data monitoring, disease management, and personalized coaching. The platform includes a blood glucose device that connects to a smartphone, providing insights and guidance to patients. The company reported revenue growth in the third quarter of 2017 and is forecasting strong sequential revenue growth going forward. The MyDario kit is fully reimbursed in several countries and has partial insurance coverage in the U.S. DarioHealth plans to expand its sales channels and increase its subscription services. The company aims to expand its footprint in Europe and support additional chronic conditions in the future. DarioHealth also plans to capitalize on the data it collects to develop predictive models and artificial intelligence for healthcare providers.
CustomersInvestment
growth-positive
DarioHealth Launches Version 3.5 of its MyDario App to Support iPhone 7 and iPhone 8
DarioHealth Corp. has announced the availability of an update to its MyDario app, which includes support for the Lightning compatible device for iPhone 7 and iPhone 8. The update ensures that users will be able to receive the same quality user experience with DarioHealth on the latest Apple devices. The new features introduced in the update include a weight log and a barcode scanner, which allows for easier carb counting. DarioHealth believes that these features will increase customer engagement and help customers keep better track of their carbohydrate intake.
Customers
growth-positive
Dario Health Expands Smart Diabetes Platform to German Market
DarioHealth, an Israeli-based global digital health company, has announced the expansion of its smart diabetes platform to the German market. This makes the platform commercially available in nine countries worldwide. The Dario Blood Glucose Monitoring System is an all-in-one compact glucose meter that connects directly to a smartphone via the Dario app, providing people with diabetes a simple and accurate way to manage their condition. The company expects the launch in the German market to help it reach its Q4 revenue goals and FY2017 annual milestones.
Expand
growth-positive
DarioHealth Partners with Byram Healthcare to Further Expand Insurance Health Coverage for U.S. Consumers
DarioHealth Corp. has announced a strategic agreement with Byram Healthcare to expand its insurance coverage provider network. Byram Healthcare is a market-leading distributor of reimbursable medical supplies in the United States. This partnership will accelerate DarioHealths market penetration in the insurance reimbursable market for its U.S. consumers. With the addition of Byram Healthcare, DarioHealth expects to cover 30% of consumers in the U.S. diabetes market. The company has already received positive feedback and has covered major insurance plans such as Aetna, United HealthCare, and various Blue Cross Blue Shield programs.
Partners
growth-positive
DarioHealth Receives "First Choice" Recognition in the UK
DarioHealth Corp. has been named the First Choice by the CCGs for all type 1 diabetics in three UK regions. This recognition by the Clinical Commissioning Groups is a significant breakthrough for DarioHealth, as it will help the company gain more market share in the UK. The Dario all-in-one diabetes management system has been praised by healthcare professionals for its design and utility. DarioHealth is a leading global digital health company that provides mobile health and big data solutions for diabetes management.
Customers
growth-positive
DarioHealth Signs NBA Legend Dominique Wilkins as Brand Ambassador
DarioHealth Corp. has announced a brand ambassador partnership with NBA great Dominique Wilkins to advance awareness of MyDario, drive growth of new customers, and increase market penetration. Wilkins, who was diagnosed with type 2 diabetes after his retirement, will use MyDario to monitor his blood glucose levels and promote a healthier lifestyle. The partnership will involve collaboration on social media, digital marketing, and public appearances. DarioHealth is a global digital health company that provides mobile health and big data solutions for diabetes management.
Customers
growth-positive
DarioHealth Corp. Announces $5.1 Million Private Placement Led by OurCrowd Qure - Israeli Digital Health Specialized Fund
DarioHealth Corp. has raised $5.1 million in a private placement transaction led by OurCrowd Qure. The funding will be used to accelerate adoption across existing markets and expand into new geographies. The successful fundraising round indicates strong support and belief in DarioHealths product, vision, and growth strategy. The companys smart diabetes management solution combines a blood glucose monitoring system, smartphone app, website portal, and treatment tools. DarioHealth aims to personalize treatment and advance medical knowledge by combining and analyzing consumer health data. The private placement transaction included the sale of common stock and warrants. DarioHealth intends to use the net proceeds for sales and marketing efforts, working capital, and general corporate purposes.
Investment
growth-positive
DarioHealth Corp. Announces $5.1 Million Private Placement Led by OurCrowd Qure - Israeli Digital Health Specialized Fund
DarioHealth Corp. has raised $5.1 million in a private placement transaction led by OurCrowd Qure, Israels First Exclusive Digital Health Fund. The funding will be used to accelerate adoption across existing markets and expand into new geographies. The successful fundraising round indicates strong support and belief in DarioHealths product, vision, and growth strategy. The companys Chairman and CEO, Erez Raphael, expressed gratitude for the investors support and stated that the funding will help accelerate the adoption of their innovative remote glucose monitor platform. The private placement transaction included the sale of shares of common stock and warrants. DarioHealth intends to use the net proceeds for sales and marketing efforts, working capital, and general corporate purposes.
Investment
growth-positive
DarioHealth Launches New Digital Platform and Online Store in Canada
DarioHealth Corp. has announced the launch of an online store in Canada in collaboration with A&D Medical and Bayshore Specialty Rx Ltd.s online pharmacy Diabetes Express. The partnership allows for a complete online experience for Dario products and supplies, including handling of prescriptions and interaction with insurers. DarioHealth will be responsible for digital marketing, while Diabetes Express will handle reimbursement and the prescription process. The launch of the online store is part of DarioHealths strategy to make life easier for people with diabetes. The company expects the partnership to offer a complete and robust offering to the diabetes population in Canada.
CustomersPartners
growth-positive
DarioHealth's US market doubles revenue, reaches 5K users for connected glucometer
DarioHealth, a smartphone-connected glucometer company, reported over 100% growth in revenue in the second quarter of 2016, bringing in $669,000. The company also reported 4,900 registered users, 2,300 monthly active users, and a cash balance of $6.4 million. DarioHealth plans to increase sales and recurring subscription revenues in the second half of 2016. They have a direct-to-consumer model and believe they have the right digital marketing strategy to reach consumers. In July, DarioHealth signed an agreement with healthcare distributor GEMCO Medical to expand its presence in the United States. They also began offering their system directly to consumers in Australia. DarioHealth expects sales to accelerate in the second half of 2016 and provide a foundation for long-term growth.
CustomersPartners
growth-positive
LabStyle Innovations Now DarioHealth
Labstyle Innovations Corp. is changing its corporate name to DarioHealth Corp. to reflect its growth and development in the digital health and mHealth space. The companys flagship product, The Dario™ Smart Diabetes Management Solution, combines a blood glucose meter and a smartphone app for diabetes management. The name change is expected to help the company extend its offerings to a larger global market. The new name will be effective on July 28, 2016. Labstyle Innovations Corp. will continue to trade on Nasdaq under the ticker DRIO.
Expand
growth-positive
LabStyle Innovations seeks to raise $11.5m
LabStyle Innovations Corp., a medical device company, has received FDA approval for its device that measures blood sugar using a smartphone. The company is seeking to raise $11.5 million in capital and upgrade its stock from the Nasdaq OTC market. LabStyle Innovations plans to use the funds to expand production capacity, develop software, and increase sales and marketing efforts. The company is still posting negative cash flow, but has seen a significant increase in its share price since listing on Nasdaq. LabStyle Innovations faces competition from larger companies such as Abbott Laboratories and Johnson & Johnson.
InvestmentExpand
growth-positive
An Israeli app for diabetics goes global
Labstyle Innovations, the maker of the Dario system, a smartphone-based diabetes monitoring and insulin delivery system, is experiencing growth in the market. The Dario system allows diabetics to measure their blood sugar levels and administer insulin using their smartphones. The system automatically uploads data to the cloud for analysis by medical personnel and provides users with reminders, graphs, and charts about their blood sugar levels. The system is currently available in several countries through national health insurance plans, and Labstyle Innovations is working on deals with insurance companies and government insurance offices in other countries, including the US. Labstyle Innovations plans to expand the technology to other chronic conditions in the future. The company is experiencing positive reviews and expects expansive demand for the product.
CustomersPartners
growth-positive
Dario Turns Diabetics' Smartphones Into Trendy Glucometers
LabStyle Innovations, an American enterprise with Israeli subsidiaries, has developed Dario, a Diabetes Management System that incorporates an integrated smartphone-based glucometer. The device allows users to measure their glucose levels and view the results on their smartphones screen. Dario also includes data management and analysis tools, a network for sharing results with clinicians, and a reminder system. The product is prescription-based and is sold in the US via mail order or e-commerce. LabStyle Innovations plans to be a dominant player in the diabetic market and is working on expanding Darios capabilities for other body fluid testing.
Customers
DarioHealth Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 237 |
| Team members | 9 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
DarioHealth Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 95/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514668466 |
| Crunchbase | labstyle-innovations |
| Phone | +97248273085 |
| Creator | Sophie Pollock |
| Creator email | pollos@blair.edu |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-04-04T00:00:00.000Z |
| Created | 2014-06-23T00:00:00.000Z |
| Status detail | Public on NASDAQ on Feb, 2013; |